

1 **Modulation of motor behavior by the mesencephalic locomotor region**

2
3 Daniel Dautan^{1*}, Adrienn Kovács², Tsogbadrakh Bayasgalan², Miguel A. Diaz-Acevedo¹,
4 Balazs Pal² and Juan Mena-Segovia^{1*}

5
6 ¹ Center for Molecular and Behavioral Neuroscience, Rutgers University, Newark, NJ,
7 USA

8 ²Department of Physiology, University of Debrecen, Faculty of Medicine, 4012 Debrecen,
9 Hungary

10
11 *Correspondence:

12 Center for Molecular and Behavioral Neuroscience, Rutgers University, Newark, NJ, USA
13 E-mail: juan.mena@rutgers.edu

14
15 DD current address: Department of Genetic of Cognition, Italian Institute of Technology,
16 Genova, Italy. E-mail: Daniel.dautan@iit.it

17
18 **Keywords:** pedunculo pontine; cuneiform; glutamatergic; locomotion; muscle tone;
19 connectivity; heterogeneity.

20
21 **Number of figures:** 7

22 **Number of words:** Abstract: 147; Main Text: 4669.

23 **Acknowledgments:**

24
25 This research was supported by an NIH grant NS100824 (J.M.S.), a NJ-DOH grant
26 CSCR20IRG008 (J.M.S.), a NARSAD Young Investigator Award (J.M.S.), the Hungarian
27 National Brain Research Program (B.P.), the OTKA Bridging Fund of the University of
28 Debrecen (B.P.) and Rutgers University. The authors are grateful to Dr. Péter Szücs
29 (Department of Anatomy, Histology and Embryology, Medical Faculty, University of
30 Debrecen) for providing access and for his kind help in Neurolucida reconstructions, and
31 Prof. Miklós Antal (Department of Anatomy, Histology and Embryology, Medical Faculty,
32 University of Debrecen) for providing VGLUT2-cre mice for breeding. We also thank Dr.
33 Nadine Gut for comments on this manuscript.

34 **Author contributions**

35
36 J.M.S. and D.D. conceptualized the project. D.D., A.K., T.B., and B.P. performed
37 experiments. D.D., A.K., T.B., M.D. and B.P. analyzed the data. D.D., M.D., B.P. and
38 J.M.S. wrote the original draft. All authors contributed to reviewing and editing the final
39 version of the manuscript. J.M.S. supervised the project.

42 **Abstract**

43 The mesencephalic locomotor region (MLR) serves as an interface between higher-order
44 motor systems and lower motor neurons. The excitatory module of the MLR is composed
45 of the pedunclopontine nucleus (PPN) and the cuneiform nucleus (CnF), and their
46 activation has been proposed to elicit different modalities of movement, but how the
47 differences in connectivity and physiological properties explain their contributions to motor
48 activity is not known. Here we report that CnF glutamatergic neurons are
49 electrophysiologically homogeneous and have short-range axonal projections, whereas
50 PPN glutamatergic neurons are heterogeneous and maintain long-range connections,
51 most notably with the basal ganglia. Optogenetic activation of CnF neurons produced
52 fast-onset, involuntary motor activity mediated by short-lasting muscle activation. In
53 contrast, activation of PPN neurons produced long-lasting increases in muscle tone that
54 reduced motor activity and disrupted gait. Our results thus reveal a differential contribution
55 to motor behavior by the structures that compose the MLR.

56

57 **Introduction**

58 The mesencephalic locomotor region (MLR) is a functionally-defined midbrain area
59 composed of the pedunclopontine nucleus (PPN) and the cuneiform nucleus (CnF)
60 which has been typically described as an output station of forebrain systems reaching
61 lower motor circuits¹⁻³. Early experiments defined the MLR by demonstrating that
62 electrical stimulation of this region induced a locomotor response in decorticated cats^{4,5}.
63 More recently, optogenetic experiments revealed that the motor function of the MLR is
64 dependent on excitatory transmission from glutamatergic neurons^{6,7}, which is the most

65 prominent cell type in the MLR^{8,9}. In the last two decades, a role for these circuits in gait
66 and posture has been proposed^{10–13}. Moreover, degeneration of neurons in the MLR may
67 underlie some of the motor impairments in Parkinson's disease^{14–19}. Deep brain
68 stimulation into the PPN has been shown to produce some improvements in abnormal
69 gait based on the idea that the output from the MLR is excitatory^{20–23}. However, it is not
70 fully understood how excitatory MLR neurons contribute to motor behavior and how motor
71 functions are associated with different neuronal types in the MLR.

72

73 The PPN, the largest component of the MLR, is highly heterogeneous. It is composed of
74 three neurotransmitter-defined cell types: cholinergic, GABAergic and glutamatergic
75 neurons. Among PPN glutamatergic neurons, a high degree of variability has been
76 reported in their neurochemical composition⁸, connectivity²⁴ and firing properties²⁵.
77 Comparatively less is known about the CnF. Recent reports show that activation of CnF
78 glutamatergic neurons induces a robust motor activation that is functionally distinct from
79 the activation of PPN neurons, suggesting a functional specialization of MLR neurons^{7,12}.
80 PPN and CnF are contiguous structures, the borders of which are not well defined²⁶, and
81 this imposes a challenge for unambiguously separating both populations. Furthermore,
82 there is a certain level of interconnectivity that accounts for an additional degree of
83 difficulty in the interpretation of functional studies. We, therefore, sought to identify the
84 functional properties of PPN and CnF neurons and their involvement in motor control.

85

86 We used a range of electrophysiological, behavioral and anatomical techniques to dissect
87 the properties of glutamatergic neurons in the PPN and CnF and identify their specific

88 contributions to motor function and muscle activity. Our results establish fundamental
89 differences in the properties and functions of the PPN and CnF.

90

91 Results

92 Input/output connectivity of PPN and CnF with segregated motor circuits

93 To determine the afferent and efferent connectivity of MLR glutamatergic neurons, we
94 used Cre-dependent anterograde and retrograde viral tracing strategies in VGLUT2-Cre
95 mice. Given the proximity of MLR structures, only microinjections that were strictly
96 confined to the borders of the PPN or the CnF were considered further. We used the
97 immunolabeling of choline acetyltransferase (ChAT) to delimit the boundaries of the PPN
98 and the ventral border of the CnF^{26–29}. CnF is ventrally bordered by the PPN and dorsally
99 by the central nucleus of the inferior colliculus and fibrodendritic lamina³⁰. A glutamatergic
100 neuron was considered to belong to the PPN if it was located within 100 μ m of the closest
101 cholinergic neurons (**Fig. 1A**), or to the CnF if it was located at least 100 μ m dorsally to
102 cholinergic neurons and ventral to the cIC (**Fig. 1B**). If more than 5% of virus-labeled
103 neurons were located outside the borders of the targeted structure, the data from the
104 animal were excluded (**Supplementary Fig. 1A**).




Figure 1. Segregation of MLR structures by viral transduction.

Viral injection volume was adjusted to be restricted within the border of the PPN (**A**) or the CnF (**B**) using as a marker the expression of choline acetyltransferase (ChAT; 100 μ m radius). The dorsal and ventral border of the PPN was defined as 100 μ m distance from the outer cholinergic neuron soma (**A**), whereas the ventral border of CnF was 100 μ m further from cholinergic neurons (**B**).

105

106 To label the axonal projections and synapses originating in the PPN and CnF, we
107 transduced glutamatergic neurons with a reporter expressing cytosolic green fluorescent
108 protein (GFP) in the presence of Cre recombinase and a red fluorescent protein (mRuby)
109 under the control of the promoter for the pre-synaptic marker synaptophysin (AAV-hSyn-
110 FLEX-GFP-2A-Synaptophysin-mRuby, PPN n = 3; **Fig. 2A1**; CnF n = 3; **Fig. 2A2**). We
111 next mapped the synaptophysin expression across the brain and spinal cord using high-
112 resolution confocal imaging (**Fig. 2B, F**). No differences in the number of transduced
113 neurons (GFP⁺) between PPN and CnF were observed (**Fig. 2C, Supplementary Fig.**
114 **1B-C**). However, the density of synapses (mRuby⁺/GFP⁺ puncta) was higher in the PPN
115 group compared to the CnF group (**Fig. 2D**). We next compared the distribution of
116 synapses across the brain between both groups (**Fig. 2B, E**). We found comparatively
117 more innervation by PPN than CnF neurons in the basal ganglia (PPN: 0.336 ± 0.089
118 pixels/100 μm^2 ; CnF: 0.095 ± 0.032 pixels/100 μm^2 ; Wilcoxon rank-sum test $P = 0.0369$;
119 **Fig. 2F**), as well as in individual structures such as the dorsal raphe (PPN: 0.56 ± 0.121
120 pixels/100 μm^2 ; CnF: 0.047 ± 0.023 pixels/100 μm^2 ; $P = 0.0292$) and the dorsal
121 periaqueductal gray area (dPAG; PPN: 0.251 ± 0.078 pixels/100 μm^2 ; CnF: 0.176 ± 0.034
122 pixels/100 μm^2 ; $P = 0.037$), in agreement with previous tracing studies^{31–33}. In contrast,
123 the innervation originated in CnF glutamatergic neurons was mostly concentrated in the
124 midbrain and similar to the PPN (PPN: 0.25 ± 0.028 pixels/100 μm^2 ; CnF: 0.17 ± 0.029
125 pixels/100 μm^2 ; $P = 0.0562$) and the pons (PPN: 0.14 ± 0.03 pixels/100 μm^2 ; CnF: $0.12 \pm$
126 0.033 pixels/100 μm^2 ; $P = 0.56$; **Fig. 2G**), including the tectal area, the parabrachial
127 nucleus, PAG, and the ventral gigantocellular nucleus, in agreement with previous
128 studies^{34–36}. Furthermore, PPN but not CnF neurons show synaptic labeling in the





Figure 2. Axonal distribution of PPN and CnF glutamatergic neurons.

A-B, Following injection of AAV-DIO-GFP-2A-synaptophysin-mRuby (**A**) restrained to the PPN (**A1**) or the CnF (**A2**) borders, we observed widespread distribution of GFP-labeled axons (**B**). **C-D**, Quantification of the total count of GFP-positive soma (PPN: 504.66 ± 58.42 ; CnF: 518.33 ± 54.67 , one-way ANOVA $F_{(1,5)} = 0.03$, $P = 0.87$) and overall synaptic density (PPN: 0.27 ± 0.024 pixels/100 μ m²; CnF: 0.18 ± 0.02 pixels/100 μ m², one-way ANOVA $F_{(1,86)} = 7.64$, $P = 0.007$). **E**, Segregated synaptophysin labeling across the brain revealed distinct patterns of innervation by PPN and CnF glutamatergic neurons, particularly in the basal ganglia, forebrain, thalamus, midbrain, medulla and cerebellum (Wilcoxon test). **F**, Fluorescent micrographs illustrating GFP and synaptophysin labeling in the striatum following PPN transduction. **G**, Distribution of axons in the brainstem following PPN and CnF injections. **J**, Synaptic distribution in a cervical segment of the spinal cord. **K**, Axonal reconstructions in typical examples of cervical, thoracic, lumbar, and sacral spinal cord segments following unilateral PPN injection. * $P < 0.05$. All experiments have been replicated at least 3 times. Single data are represented by small dots. All data are represented as mean \pm SEM.

130 striatum, the substantia nigra pars compacta (4.27 ± 0.12 pixels/ $100\mu\text{m}^2$), cerebellum
131 (4.19 ± 0.04 pixels/ $100\mu\text{m}^2$), the dorsal brainstem (vestibular nucleus: PPN 0.77 ± 0.02
132 pixels/ $100\mu\text{m}^2$, CnF: 0 pixels/ $100\mu\text{m}^2$; medullary reticular nucleus, MdV: PPN 0.4 ± 0.01
133 pixels/ $100\mu\text{m}^2$, CnF: 0 pixels/ $100\mu\text{m}^2$; **Fig. 2G**) and the spinal cord (**Fig. 2J**). PPN
134 glutamatergic projections to the spinal cord were observed at all segments (**Fig. 2K**), but
135 the synaptic density was not quantified. Following axonal reconstructions of randomly
136 selected cervical, thoracic, lumbar and sacral segment sections (**Fig. 2K**), we found that
137 PPN projections follow the rubrospinal tract and decussate in laminae 5-7, making dense
138 synapses (mRuby signal) that seem to avoid motor neurons, as revealed with ChAT-
139 immunostaining, which is expressed in spinal neurons. Taken together, these findings
140 suggest that PPN directly projects to structures involved in different modalities of
141 movement (i.e. basal ganglia, brainstem, cerebellum and spinal cord), whereas CnF
142 sends projections to structures involved in the execution of movement (i.e. ventral
143 gigantocellular nucleus; **Supplementary Fig. 2**).

144

145 Next, to identify the inputs to the glutamatergic neurons of the PPN and CnF, we used a
146 monosynaptic retrograde labeling strategy in VGLUT2-cre mice (RvDG-YFP). Because
147 the specificity of the retrograde tracing is conferred by the expression of the helper
148 viruses, we adjusted the volume of the helper mix (AAV-DIO-TVA-mCherry, AAV-DIO-
149 Rg, 1:1) to selectively target PPN (**Fig. 3A**; n=3) or CnF (**Fig. 3B**; n=3) according to the
150 criteria described earlier. Starter neurons (mCherry-/YFP-positive) within the PPN and
151 CnF were located within the border of each structure (**Fig. 3C**). The overall number of
152 input neurons (YFP-positive) was larger in the PPN group compared to the CnF group



153

154 (Fig. 3D). After normalization by the number of starter neurons, the number of input

155 neurons was still larger in the PPN group (PPN: 4.73 ± 1.27 , CnF: 2.28 ± 0.94 , $P = 0.027$).

156 We found a larger number of input neurons to the CnF originating in the colliculi (PPN: 22

157 ± 1.74 , CnF: 39.66 ± 8.46 , Wilcoxon rank-sum $P = 0.0033$; **Fig. 3E**), the PAG (PPN: 5.06
158 ± 0.44 , CnF : 8.52 ± 0.92 , $P = 0.0275$) and the precuneus (PPN: 7.46 ± 0.61 , CnF: 15.238
159 ± 1.89 , $P = 0.0175$), whereas a larger number of input neurons to the PPN originated in
160 the PnO (PPN: 7.47 ± 0.21 , CnF: 2.21 ± 1.46 , $P = 0.0234$, **Fig. 3H**), the striatum (PPN:
161 2.66 ± 1.55 , CnF : 0.33 ± 1.15 , $P = 0.04$, **Fig. 3I**), the ZI (PPN: 4.33 ± 0.15 , CnF: $1.18 \pm$
162 0.70 , $P = 0.025$) and the motor cortex (PPN: 4.66 ± 0.66 , CnF : 1.52 ± 1.52 , $P = 0.025$;
163 **Fig. 3J**). Input neurons in a subset of motor structures were observed to connect
164 exclusively with the PPN, including the SNr (PPN: 5.3 ± 0.39 , CnF : 0 ; **Fig. 3F-G**), spinal
165 cord (PPN: 7.23 ± 0.96 , CnF : 0 ; **Fig. 3K**), gigantocellular nucleus (PPN: 0.98 ± 0.22 ,
166 CnF: 0), dorsal gigantocellular nucleus (PPN: 2.16 ± 0.20 , CnF: 0), paragigantocellular
167 nucleus (PPN: 1.33 ± 0.13 , CnF: 0) and deep cerebellar nuclei (PPN: 4.22 ± 0.55 , CnF:
168 0 ; **Figure 3E-K, Supplementary Fig. 2**). Overall, the distribution of inputs to PPN
169 glutamatergic neurons is far more widespread than the distribution of inputs to CnF
170 glutamatergic neurons and largely overlaps with the PPN/CnF output targets (**Figure 3L**).
171 Combined, these results reveal differences in the input/output connectivity of PPN and
172 CnF glutamatergic neurons with separate motor circuits (**Supplementary Figure 2**).


173

174 **Glutamatergic PPN neurons are physiologically distinct to CnF neurons**

175 To characterize the physiological properties of MLR glutamatergic neurons, we obtained
176 brain slices for *ex vivo* recordings of identified PPN ($n=77$) and CnF ($n=41$) glutamatergic
177 neurons of VGLUT2-tdTomato mice (**Figure 4, Supplementary Fig. 3, Supplementary**
178 **Table 2-3**). From the recorded td-Tomato-positive neurons, randomly selected subsets
179 (PPN $n=15$, CnF $n=11$; **Fig. 4A-B**) were subsequently labeled and reconstructed,

180 revealing that CnF glutamatergic neurons have a significantly larger number of main
181 dendrites, nodes and endings (**Fig. 4C-D; Supplementary Table 2**). Based on the
182 classical electrophysiological classification of PPN neurons^{37,38} (**Supplementary Figure**
183 **3, Supplementary Tables 2-3**), we defined functional subgroups based on changes of
184 spike frequency adaptation with increasing depolarization³⁹ and classified neurons in 3
185 groups: non-adapting, slowly adapting and rapidly adapting (**Fig. 4E-G**). In the PPN,
186 30.2% of all neurons (13/43 neurons) were non-adapting and were located predominantly
187 in the lateral regions, whereas 21% (9/43 neurons) were slowly adapting and 48.8%
188 (21/43 neurons) were rapidly adapting. In contrast, in the CnF the large majority of
189 neurons (85.7%, 24/28 neurons) were rapidly adapting, and non-adapting and slowly
190 adapting constituted equal smaller proportions (7.15%, 2/28 neurons for each category;
191 **Fig. 4H**). Thus, the responses of MLR glutamatergic neurons to spike adaptation reveal
192 important biophysical group differences in the composition of the PPN and the CnF
193 ranging from firing frequency to adaptation index (**Supplementary Fig. 4,**
194 **Supplementary Table 2**).

195
196 Next, because neurons in the MLR region have been reported to display high-threshold
197 membrane potential oscillations^{40,41}, we sought to characterize the oscillatory activity of
198 glutamatergic neurons of the PPN and CnF. Oscillatory activity in the 10-20 Hz range was
199 present in PPN glutamatergic neurons (n=24 neurons) and was sensitive to TTX (**Fig. 4I**).
200 In contrast, oscillatory activity in the 20-40 Hz range was present in the CnF (n=19
201 neurons) but it was weaker and largely insensitive to TTX (**Fig. 4J**). Power spectra
202 revealed similar average frequency ranges of oscillatory activity in the PPN and CnF, but



204 with a greater standard deviation in CnF neurons. TTX-resistant oscillations were virtually
205 absent in both structures (**Supplementary Table 2**). Furthermore, persistent sodium
206 currents were observed predominantly in the PPN (9/11 neurons, range from 26 to 58.7
207 pA, average 32.5 ± 4.5 pA; **Fig. 4K**), and to a much lesser extent in the CnF (3/7 neurons,
208 range from 7 to 22.2 pA, average 12.4 ± 4.9 pA; **Fig. 4L**), suggesting their likely
209 contribution to the oscillatory activity observed in PPN neurons. In summary, PPN
210 glutamatergic neurons form a heterogeneous group and display robust, wide-range
211 oscillatory activity and the presence of persistent sodium currents. In contrast, CnF
212 glutamatergic neurons are largely fast-adapting and mostly lack persistent sodium
213 currents.

214

215 **PPN and CnF activation produces contrasting effects on motor activity**

216 The differences in the connectivity and physiological properties between PPN and CnF
217 reported here suggest that neurons in each structure are recruited by different motor
218 circuits and that their dynamics of activation differ. Recent reports have shown that CnF
219 neurons modulate speed locomotion^{6,12,42}, whereas PPN neurons have been suggested
220 to modulate exploratory locomotion⁷ and locomotion pattern¹². To elucidate the extent of
221 overlap of PPN and CnF function in the context of motor behavior, we used an optogenetic
222 strategy to stimulate glutamatergic neurons while mice were tested in a battery of motor
223 tasks. We unilaterally transduced ChR2 into the PPN or the CnF of VGLUT2-Cre mice
224 and implanted an optic fiber to deliver blue light and activate ChR2 (**Supplementary Fig.**
225 **1A**). First, we determined the effects in the open field (40x40cm, **Fig. 5A**). Stimulation of
226 CnF (n=6 mice), but not PPN (n=8 mice), increased motor activity (CTRL: n=8 mice; **Fig.**

227 **5B-E)**. The analysis of the individual trials revealed that stimulation of CnF glutamatergic
228 neurons robustly increased the distance traveled compared to the baseline (**Fig. 5B**). In
229 contrast, stimulation of PPN glutamatergic neurons (**Fig. 5C**) significantly reduced the
230 distance traveled. To determine whether the stimulation effects were dependent on the
231 behavioral state of the animal, we separated the stimulation trials based on whether
232 animals were moving or not. We found that CnF stimulation increases the distance
233 traveled and speed regardless of the behavioral state of the animal (**Fig. 5D**), whereas
234 PPN effects were only visible during ongoing movement (**Fig. 5E**). Because the effects
235 of PPN stimulation reported here contrast with previous studies that reported an increase
236 in motor activity during PPN activation^{6,7}, we next explored whether different stimulation
237 protocols may account for the differences between studies. We used three stimulation
238 frequencies (1, 10 and 20Hz, 1s ON/9s OFF; **Fig. 5F-G**) and found that, in line with the
239 effects reported above, the effect of PPN stimulation was consistently inhibitory, whereas
240 the increase in motor activity elicited by CnF stimulation was frequency-dependent (**Fig.**
241 **5F-G**). No differences in the time spent in center vs periphery of the open field were
242 detected (**Fig. 5H**), thus ruling out an anxiogenic effect of the stimulation. To further
243 characterize the frequency-dependent effects reported above, we tested a different cohort
244 of CnF-transduced and -implanted animals (n=6) in a larger open field (80 x 80cm) with
245 randomized stimulation frequencies ranging from 0.1 Hz to 30 Hz (1s ON/9s OFF). We
246 found that all stimulation frequencies increased the distance traveled (**Supplementary**
247 **Fig. 5A**) with a maximum effect observed at 12.5Hz and that the effect was restricted to
248 the duration of the stimulation (**Supplementary Fig. 5B, Video 1**). These results reveal
249 that CnF stimulation increases the distance traveled by generating robust and consistent




Figure 5. Locomotor effects following stimulation of PPN and CnF glutamatergic neurons.

A, Trace examples of control, PPN, and CnF stimulated animals tested in the open field. Red circle represents the center of the arena. The behavior was recorded at a resolution of 30 frame-per-second. **B-C**, Normalized distance traveled (5ms bin) during individual 10Hz stimulation of CnF (**B**) or PPN (**C**) glutamatergic neurons; control animals (gray; wild-type) received the same experimental treatment (two-way MANOVA groups x stimulation: group effect $F(2,491)=198.21$, $P=0.00001$, stimulation effect $F(2,491)=503.43$, $P=0.00001$, interaction effect $F(4,491)=201.55$, $P=0.00001$; posthoc Bonferroni, $P_{CnFstim_PPNstim}=0.0001$, $P_{CnFstim_CTRLstim}=0.0001$, $P_{PPNstim_CTRLstim}=0.0001$). The line above represents the statistical difference of the distance traveled compared to the baseline (1s). **D-E**, Distance traveled per 5ms bin during individual stimulation of CnF (**D**) or PPN (**E**) glutamatergic neurons during resting (black) or during spontaneous movement (3-way mixed ANOVA structure x state x stimulation: stim effect $F(2,443)=9$, $P=0.0001$; structure: $F(1,443)=79.95$, $P=0.00001$, state: $F(1,443)=2792.70$, $P=0.00001$, interaction: $F(4,443)=30.72$, $P=0.00001$, posthoc Bonferroni $P_{PPN_mobile_immobile}=0.0001$; $P_{cnf_mobile_immobile}>0.05$). The line above represents the statistical difference of the distance traveled compared to the baseline (1s). **F-G**, Total distance traveled and average speed (in m/s) following stimulation at 1Hz, 10Hz or 20Hz (20ms pulse; distance traveled: two-way RM-ANOVA: $F_{group}(2,62)=0.86$, $P=0.433$, $F_{frequency}(2,62)=5.22$, $P=0.0102$, $F_{interaction}(4,62)=6.83$, $P=0.0003$, post hoc: 1Hz: $P_{ctrl-CnF}=0.256$, $P_{ctrl-PPN}=0.11$; 10Hz: $P_{ctrl-CnF}=0.002$, $P_{ctrl-PPN}=0.25$; 20Hz: $P_{ctrl-CnF}=0.002$, $P_{ctrl-PPN}=0.035$; average speed: $F_{group}(2,62)=2.71$, $P=0.1046$, $F_{frequency}(2,62)=1.93$, $P=0.16$, $F_{interaction}(4,62)=5.55$, $P=0.0014$, post hoc: 1Hz: $P_{ctrl-CnF}=0.11$, $P_{ctrl-PPN}=0.14$; 10Hz: $P_{ctrl-CnF}=0.008$, $P_{ctrl-PPN}=0.25$; 20Hz: $P_{ctrl-CnF}=0.007$, $P_{ctrl-PPN}=0.031$). **H**, Percentage of time spent in the center of the arena ($F(2,20)=0.30$, $P=0.7426$). **I**, Representative traces of PPN and CnF stimulated animals on the constant-speed treadmill. **J-K**, Distance traveled and average distance from the front of the treadmill following stimulation at 10Hz (distance traveled: one way ANOVA $F(2,21)=24.03$, $P=0.00001$, Bonferroni $P_{PPN_CTRL}=1.0$, $P_{CTRL_CnF}=0.0001$, $P_{PPN_CnF}=0.0001$; average speed: $F(2,21)=17.41$, $P=0.0001$, Bonferroni $P_{PPN_CTRL}=0.714$, $P_{CTRL_CnF}=0.0001$, $P_{PPN_CnF}=0.001$; distance to the front: ($F(2,21)=14.44$, $P=0.0001$, Bonferroni $P_{PPN_CTRL}=0.0001$, $P_{CTRL_CnF}=0.715$, $P_{PPN_CnF}=0.001$). * $P<0.05$. All experiments have been replicated at least 3 times. Whisker plot are representing mean, median, standard error and 25/75th percentile. All data are represented as mean \pm SEM.

251 bouts of motor activity, whereas stimulation of PPN neurons briefly reduces exploratory
252 locomotion.

253

254 To determine whether the reduction in motor activity observed following PPN stimulation
255 was the consequence of altering the behavioral state during exploratory locomotion (i.e.
256 as evaluated above in the open field) or rather a pure motor effect, we next tested the
257 mice during forced locomotion (custom-made motorized treadmill, 3m/min constant
258 speed), in which animals keep up walking at the front of the treadmill (as seen in controls;
259 **Fig. 5I-K**). In the PPN group, blue light stimulation caused the mice to stop locomotion
260 and lag at the rear of the treadmill (**Fig. 5I-K, Supplementary Fig. 5C**). As expected,
261 mice in the CnF group spent most of the time at the front of the treadmill and had a
262 significantly larger traveled distance than control and PPN groups (**Fig. 5I-K**). These
263 results suggest that activation of PPN glutamatergic neurons reduces locomotion by
264 decreasing overall motor activity.

265

266 Because the MLR, and specifically the PPN, have been proposed to have a key role in
267 gait and balance, we next tested the mice in the elevated grid walk test, which evaluates
268 skilled coordinated movements requiring sensorimotor integration⁴³. Mice were placed on
269 a 20 x 40 cm elevated grid (grid size 1.5 cm) and allowed to explore freely for 20 minutes
270 (**Fig. 6A-B**). Compared to controls, stimulation of PPN neurons produced a significant
271 reduction in the distance traveled, distance to the center of the grid and movement speed
272 (PPN n=6; control n=11; **Fig. 6B-D, Supplementary Fig. 5D**). Furthermore, PPN
273 stimulation increased the number of foot slips (**Fig. 6E-F, Video 2**) whereas the number




Figure 6. Modulation of gait by PPN glutamatergic neurons.

A, Representation of the elevated grid walk test. **B**, Representative traces in control and PPN groups (CnF group is not shown, see text for details). **C-D**, Distance traveled (t-test two-tail $t(28)=7.8146$, $P=0.00001$) and average distance to the center ($t(28)=6.34$, $P=0.00001$) following 10Hz stimulation. **E**, Representative images of mice making footslips during the elevated grid-walk test. **F**, The total number of footslips ($t(15)=5.29$, $P=0.00001$). * $P<0.05$. All experiments have been replicated at least 3 times. Whisker plot are representing mean, average, standard error and 25/75th

274

275 of rearing events decreased (**Supplementary Fig. 5E**), suggesting a disrupted
276 sensorimotor integration. This effect likely contributed to the markedly reduced
277 exploration of the grid area observed only in mice of the PPN group. In contrast,
278 stimulation of CnF neurons (n=6 mice) resulted in mice jumping off the grid as a
279 consequence of the robust motor activation, despite using lower frequencies and lower
280 laser power, and therefore these experiments were not quantified. Altogether, these
281 results indicate that activation of CnF glutamatergic neurons produced motor responses
282 with no voluntary control, i.e., regardless of the behavioral context, and the intensity of
283 the response was only determined by the frequency of stimulation. On the other hand,
284 activation of PPN glutamatergic neurons blocked distinct components of motor activity
285 regardless of the frequency of stimulation, including locomotion and gait.

286

287 **Differential modulation of muscle activity by PPN and CnF neurons**

288 Classically, the function that defines the MLR is the modulation of locomotion. Despite
289 both PPN and CnF providing excitatory innervation to motor structures in the lower
290 brainstem, medulla and spinal cord, the effect of activating each neuronal group

291 separately revealed contrasting effects during motor behavior. To determine whether the
292 seemingly opposing effects on locomotion reflect a competing process between PPN and
293 CnF neurons, or rather a cooperative mechanism to produce an integrated motor output,
294 we measured the impact of each group of neurons on muscles involved in locomotion.
295 VGLUT2-Cre mice were unilaterally transduced with ChR2 in either the PPN (n=4) or the
296 CnF (n=4; control wild-type, n=3) and were bilaterally implanted with bipolar EMG
297 electrodes in both the forelimb and hindlimb biceps. Mice were recorded during
298 spontaneous behavior in their home cage and single blue light pulses (20 ms) were
299 randomly delivered (**Fig. 7A**). First, we measured the effect on the muscle tone and found
300 that blue light stimulation equally induced an increase in the EMG signal in the PPN and
301 CnF groups but followed different dynamics: CnF stimulation transiently increased the
302 RMS signal resulting in a short muscular activation, whereas PPN stimulation produced
303 a long-lasting contraction (response duration in ms: PPN: 1383.59 ± 59.50 , CNF: 384.91
304 ± 15.71 , **Fig. 7B-C**). The analysis of the first 500 ms after the onset of the blue laser
305 revealed that the magnitude of the responses between PPN and CnF groups is similar
306 (% of change 0-0.5s, PPN: 193.988 ± 13.504 , CnF: 213.378 ± 29.346 , CTRL: $-5.24 \pm$
307 4.21 , one-way ANOVA: $F(2,214)=4.89$, $P=0.0084$, post hoc Bonferroni $P_{PPN-CTRL}=0.017$,
308 $P_{PPN-CNF}=0.9$, $P_{CNF-CTRL}=0.006$), but the difference becomes evident following this initial
309 phase, denoting a long-lasting effect in the PPN group (% of change 0.5-2s, PPN:
310 $78.60 \pm 10.06\%$, CnF: $15.72 \pm 3.93\%$, CTRL: $6.66 \pm 4.55\%$, one way ANOVA
311 $F(2,214)=26.26$, $P=0.00001$, Bonferoni post hoc, $P_{PPN-CTRL}=0.0001$, $P_{PPN-CNF}=0.0001$,
312 $P_{CNF-CTRL}=0.04$, **Fig. 7B-C**). Furthermore, the response latency following PPN stimulation
313 was significantly shorter than in the CnF group (PPN: 28 ± 4.78 ms, CNF: 79.45 ± 10.58

314 ms; two-tailed t-test $t(211)=-3.58$, $P=0.0004$; **Fig. 7D**). These results suggest that PPN
 315 stimulation produces a robust and long-lasting effect on the muscle tone, contrasting with
 316 a short-lasting effect that follows the stimulation of the CnF.




Figure 7. Differential involvement of PPN and CnF glutamatergic neurons in muscle tone generation.

A, Example of electromyogram (EMG) activity recorded at the level of the biceps following laser stimulation and the conversion into root-mean-square (RMS). **B**, Raw amplitude (μV) of the RMS-EMG of ipsilateral forelimb biceps during baseline, immediately or 500 ms after single stimulation pulses delivered in the PPN, CnF or sham (0-0.5s after stimulation: one-way ANOVA $F(2,214)=5.59$, $P = 0.0001$, post hoc Bonferroni $P_{\text{PPN_vs_CTRL}}=0.004$, $P_{\text{CnF_vs_CTRL}}=0.004$, $P_{\text{PPN_vs_CnF}}=1.0$; 0.5 to 2s after stimulation: $F(2,214)=46.62$, $P=0.00001$, post hoc Bonferroni $P_{\text{PPN_vs_CTRL}}=0.0001$, $P_{\text{CnF_vs_CTRL}}=0.0001$, $P_{\text{PPN_vs_CnF}}=0.001$). **C**, Change in the RMS signal following repeated single stimulation pulses recorded at the level of the biceps (% change relative to 1s baseline: PPN: $178.60 \pm 10.06\%$, CnF: $115.72 \pm 3.93\%$, CTRL: $94.33 \pm 4.55\%$, one-Way ANOVA $F(2,214)=26.26$, $P=0.00001$; Post hoc Bonferroni $P_{\text{PPN-CnF}}=0.0001$, $P_{\text{PPN-CTRL}}=0.0001$, $P_{\text{CnF-CTRL}}=0.804$). **D**, Response latency and duration of the significant increase in the RMS signal in response to PPN or CnF stimulation (latency: $F(1,212)=6.44$, $P = 0.019$; duration: $F(1,212)=19.29$, $P=0.00001$). **E-F**, Change in the RMS signal in the ipsilateral and contralateral forelimbs biceps following stimulation in PPN ($\text{PPN}_{\text{ispi}}=218.08 \pm 17.02\%$, $\text{PPN}_{\text{contra}}=138.46 \pm 5.71\%$, Two-Way ANOVA $\text{stim} \times \text{side}$: $F_{\text{stim}}(1,401)=648.221$, $P=0.00001$, $F_{\text{side}}(1,401)=39.6$, $P=0.0001$, $F_{\text{interaction}}=242.6$, $P=0.00001$) and CnF groups ($\text{CnF}_{\text{ispi}}=117.06 \pm 5.54\%$, $\text{CnF}_{\text{contra}}=113.55 \pm 5.51\%$, two-Way ANOVA $\text{stim} \times \text{side}$: $F_{\text{stim}}(1,401)=51.29$, $P=0.00001$, $F_{\text{side}}(1,401)=1.80$, $P=0.18$, $F_{\text{interaction}}(3,401)=18.30$, $P=0.0000$). Lines represent statistical difference compared to baseline. * $P<0.05$. All experiments have been replicated at least 3 times. Whisker plot are representing mean, median, standard error and 25/75th percentile; individual data are represented by small dots. Out of range data points are reported as numbers above the histogram. All data are represented as mean \pm SEM.

317

318 We next evaluated the effect of the stimulation on the contralateral musculature.
319 Stimulation of PPN neurons produced a marked increase in the amplitude of the ipsilateral
320 biceps that was significantly larger than the contralateral biceps. In contrast, stimulation
321 of CnF neurons produced similar increases in the EMG amplitude of the ipsilateral and
322 contralateral biceps (**Fig. 7E-F, Supplementary Fig. 6**). Thus, while activation of PPN
323 neurons produces a long-lasting increase in the amplitude of the ipsilateral EMG
324 consistent with an increased muscle resistance to passive movement, the bilateral nature
325 of the short-lasting muscle activation observed after unilateral CnF stimulation is
326 consistent with the frequency-dependent bouts of locomotor activity. Further evidence
327 was obtained following CnF low- (0.1Hz) or high-frequency (5Hz) stimulation while mice
328 were held in a tail-lifted position revealing motor contractions that resemble context-
329 independent involuntary locomotion (**Video 3**). In contrast, the lasting increase in muscle
330 tone observed following PPN stimulation may act as a readiness signal that precedes
331 locomotion, suggesting that both MLR structures act in coordination to modulate the
332 motor output. These results, together with the differences in connectivity and
333 physiological properties, uncover fundamental differences in the modulation of muscle
334 activity by MLR neurons and reveal their differential roles in motor behavior.

335

336 **Discussion**

337 Neurons of the MLR have been classically identified as a critical node for the integration
338 of behavioral signals originating in forebrain systems related to the modulation of motor
339 output. The results presented in this study reveal several differences between MLR
340 substructures in terms of their connectivity, physiological properties and effects on motor

341 behavior and muscle activity. In terms of connectivity, we show that PPN neurons have
342 widespread projections to a variety of motor regions including the basal ganglia and spinal
343 cord, whereas CnF neurons mainly concentrate in the brainstem. In terms of physiological
344 properties, we show that PPN neurons comprise a heterogeneous group displaying a
345 range of adapting responses, whereas the majority of CnF neurons are fast-adapting. In
346 terms of behavior, we show that stimulation of PPN neurons decreases overall motor
347 activity whereas CnF stimulation produces robust and highly-reliable bouts of motor
348 activity. Finally, stimulation of PPN neurons produces a prolonged increase in muscle
349 tone whereas stimulation of CnF neurons produces brief, bilateral motor contractions of
350 the limbs. Thus, the distinct attributes observed among MLR structures reveal major
351 differences in their composition and properties, and shed light into the fundamental
352 mechanisms underlying their role in motor behavior.

353

354 Our data reveal that CnF glutamatergic neurons control a stereotypical motor response
355 that scales its intensity with optogenetic frequency; from high-velocity locomotion to
356 jumping, CnF stimulation causes rapid movement of the hindlegs independent of context.
357 Subsequently, we observed that these motor effects can be explained by fast,
358 monophasic and bilateral muscle responses that mostly occurred within the 0.25 seconds
359 immediately following optogenetic CnF stimulation, in contrast with PPN stimulation which
360 caused multiphasic EMG fluctuations above baseline for an average of 1.5 seconds,
361 sometimes longer than 2 seconds. Along with the swift and consistent effect of CnF
362 stimulation on muscle and motor responses, we found that the majority of CnF neurons
363 (85.7%) are fast-adapting and strongly accommodating, suggesting that they are capable

364 of generating phasic motor responses in response to the synaptic drive by upstream
365 structures. Predominant inputs to the CnF are the superior colliculus, inferior colliculus,
366 and the periaqueductal gray area, providing a basis for the rapid transmission of sensory
367 information in contexts that signal threat. Along these lines, the only regions that showed
368 a higher density of synaptophysin-positive axons from the CnF than the PPN were the
369 hypothalamus (notably, the preoptic nucleus) and the habenula, regions involved in
370 homeostatic regulation^{44,45} and the valuation of threat^{46,47}, respectively. Overall, our data
371 support a developing theory that the CnF is involved in fast-escape behavior^{7,48} and its
372 activity is likely to be modulated to fast-incoming sensory information.

373

374 In contrast to the CnF, we show that PPN glutamatergic neurons display heterogeneous
375 features as revealed by a wider input/output connectivity map, a range of spike adaptation
376 profiles, and distinct effects on motor behavior. Whereas the CnF exhibited a more
377 restricted output domain, synaptophysin-positive PPN axons were observed in the spinal
378 cord, medulla, midbrain, cerebellum, thalamus, basal ganglia and cortex. Notably, every
379 single brain region that provides input neurons projecting to the CnF also provides input
380 to the PPN. Of the neurons we recorded in the PPN, 48.8% were fast-adapting neurons,
381 30.2% non-adapting neurons, and 21% slow adapting, suggesting a greater diversity of
382 neuronal profiles than the CnF. In terms of behavior, PPN stimulation causes stopping in
383 the open field and on the treadmill, with no significant relationship to the 10Hz and 20Hz
384 stimulation frequencies used. These findings agree with prior studies that have shown
385 decreased locomotion¹² or no increase in locomotion⁷ due to PPN stimulation at these
386 frequencies (but see⁷ for the effect at higher frequencies). Furthermore, we found that

387 stopping behavior was not the only PPN-dependent phenomenon observed. For instance,
388 on the elevated grid walk test, PPN stimulation led not only to decreased travel distance
389 and more time in the center of the grid, but also significantly more foot slips, which could
390 be interpreted in the context of a loss of motor coordination (as seen in lesions to PPN
391 cholinergic neurons⁴⁹) or reset of the motor action sequence (potentially through
392 activation of striatal interneurons³³). Nevertheless, an alternative mechanistic
393 interpretation based on the EMG data suggests that PPN neurons increase the muscle
394 tone in preparation for movement, but they lack the capability of triggering a motor output
395 by themselves. Compared to CnF-derived muscle responses, PPN stimulation caused
396 EMG activations that were multiphasic and 6-to-8 times longer on average, and produced
397 increases from baseline that were 3 times more significant. Notably, while the short-lived
398 CnF muscle activation was tightly correlated with locomotion bouts, PPN muscle
399 activation was not. Thus, the effect of PPN stimulation on the EMG revealed a prolonged
400 increase in muscle tone in the absence of movement that is consistent with the muscle
401 preparation that would be necessary to execute upstream-driven (e.g. basal ganglia)
402 motor commands. Such interpretation is congruent with the activity of PPN glutamatergic
403 neurons in arousal and behavioral activation^{25,50-52}, suggesting that PPN neurons encode
404 a readiness signal that enables motor responses. Altogether, our results uncover new
405 aspects of the heterogeneity observed in PPN glutamatergic neurons²⁴ which will most
406 certainly hold important clues to understand their multifarious contributions to behavior,
407 and highlight the necessity of future studies to address this in detail.

408

409 Growing evidence show that the function of PPN neurons is closely linked to the basal
410 ganglia. For example, PPN glutamatergic neurons are capable of reliably patterning
411 dopamine release via synapses targeting the soma, proximal dendrites, and axon initial
412 segment of SNc dopamine neurons⁵³. Furthermore, PPN glutamatergic neurons
413 innervate striatal interneurons and produce feed-forward inhibition of the striatal output³³.
414 In addition to the SNc and the striatum, our data revealed synaptophysin-positive axons
415 in the globus pallidus, endopenduncular nucleus, SNr and VTA originating in the PPN. In
416 comparison, the CnF only projects to the VTA, SNr, and globus pallidus. Altogether, basal
417 ganglia structures receive a greater density of axons from the PPN than the CnF. The
418 PPN also exclusively targets the CM-Pf thalamus, which exhibit strong control on the
419 basal ganglia by gating input to the striatum prior to the selection of goal-directed
420 actions^{54,55}, signaling saliency⁵⁶, and controlling the learning of new action-outcome
421 contingencies⁵⁷ by affecting striatal microcircuitry via control of specific interneuron
422 subpopulations^{57,58}. In terms of its afferent connectivity, our data shows that every single
423 node of the basal ganglia provides an input to the MLR (predominantly to the PPN). In
424 particular, neurons of the SNr, which constitute the main basal ganglia output in rodents,
425 is one of the primary structures providing inputs to PPN (but not CnF), as revealed by
426 ourselves and others^{6,7}. Nevertheless, despite the close bidirectional connectivity and
427 functional analogy between PPN and the basal ganglia, our data reveal that the
428 input/output connectivity map of PPN glutamatergic neurons is far more distributed and
429 intricate than previously considered. This suggests that a number of other brain regions
430 may converge on basal ganglia output-recipient PPN neurons, thus conferring them with

431 the potential to weigh the distinct synaptic inputs and select an integrated behavioral
432 output.

433

434 In the past decade, the PPN has emerged as a potential target for deep brain stimulation
435 (DBS) with a mixture of results thus rendering its use controversial⁵⁵⁻⁵⁷. Our work suggests
436 that the variability observed in the clinical setting may partly be due to differences in
437 electrode location and/or stimulation frequency and intensity. Although investigations of
438 the two excitatory structures comprising the MLR provide insight toward a general model,
439 the complexity of the MLR input/output map suggests a topography of domain-specific
440 subnetworks that must be examined specifically to interpret the variability observed
441 following PPN-DBS in clinical populations. The variety of observed motor effects due to
442 MLR stimulation between our study and others^{6,7} is likely a manifestation of different PPN
443 sub-circuits being recruited due to varying experimental manipulations (i.e. fiber optic
444 location, extension of the ChR2 transduction area and/or stimulation frequency and
445 intensity). One possibility could be that the strong effects that the PPN has on dopamine
446 release are only recruited under specific stimulation parameters and provide a basis for
447 exploratory locomotion (e.g.⁵⁹) whereas other PPN glutamatergic circuits modulate
448 muscle tone. An alternative explanation is that over-recruitment of segregate PPN
449 pathways by optogenetics results in stopping. Pathway-specific interventions controlled
450 by stimulation site, frequency, or intensity could provide a new dimension by which to
451 analyze the MLR as a versatile DBS target.

452

453 **Methods**

454 ***Animals***

455 Homozygous floxed-tdTomato (B6;129S6-Gt(ROSA)26Sortm9(CAG-tdTomato)Hze/J;
456 Jax number: 007905), VGLUT2-cre (Slc17a6tm2(cre)Lowl(also called VGLUT2-ires-Cre);
457 Jax number: 028863), and wild-type (C57bl/6, Jax number: 000664) adult male and
458 female mice were used for all experiments. All mice were housed on a normal 12:12h
459 light:dark cycle (light on at 7:00) and had unrestricted access to food and water. All
460 experiments were performed in accordance with the National Institutes of Health Guide
461 to the Care and Use of Laboratory Animals, or the Hungarian and International EU
462 Directive 2010/63/EU for all animal experiments. Approval was obtained from Rutgers
463 University Institutional Animal Care and Use Committee (16054A1D0819) and the
464 Committee of Animal Research of the University of Debrecen (5/2015/DEMAB).

465

466 ***Viral Injections/Surgery***

467 All surgeries were performed under aseptic conditions. Body temperature was maintained
468 at 37±1 degree C using a heating pad. Mice were deeply anesthetized with isoflurane
469 (1.5% to 4%, in O₂) and placed in a stereotaxic apparatus (David Kopf Instruments).
470 Ophthalmic ointment was applied. Following skin incision, a small cranial hole was made
471 above the targeted area. All measurements were made relative to bregma and
472 dorsoventral coordinates were set from dura. Viral injections were performed using a 32-
473 gauge syringe (Hamilton Syringes Neuros, #65458) at 5-7 nl/min rate using a
474 microsyringe pump (micro4, WPI). For multiple injections, an additional syringe was used
475 to avoid contamination, and syringes were thoroughly cleaned with ethanol and water

476 between each experiment. After completion of the injections, 10 to 15 min were allowed
477 before slowly withdrawing the syringe. At the end of the surgeries, animals received
478 injections of Buprenorphine (0.10mg/kg, sc) and Baytril (0.05mg/kg). Viruses used for all
479 experiments were as follows: AAV2-DIO-EF1 α -YFP (titer: 10¹²; injection in PPN: 20nL;
480 injection in CnF: 15nL, UNC Vector Core); AAV2-DIO-EF1 α -YFP-2A-synaptophysin-
481 mRuby (titer: 10¹²; injection in PPN: 10nL; injection in CnF: 10nL, Stanford Vector Core);
482 AAV5-DIO-TVA-mCherry (titer: 10¹²; injection in PPN: 10nL, injection in CnF: 7.5nL,
483 UNC Vector Core); AAV8-DIO-RG (titer: 10¹²; injection in PPN: 10nL, injection in CnF:
484 7.5nL, UNC Vector Core); RvDG-YFP (titer: 10⁸; injection in PPN: 200nL, injection in
485 CnF: 200nL, Salk Institute), AAV2-Flex-EF1a-ChR2(H134R) (titer: 10¹²; injection in
486 PPN: 20nL, injection in CnF: 15nL UNC Vector Core). Injection were delivered in the
487 following coordinates (in mm from Bregma): PPN: AP: -4.5, ML: \pm 1.25, DV: 3.3; CnF: AP:
488 -5.0, ML: \pm 1.2, DV: 2.2.

489

490 ***Histology***

491 After *in vivo* experimental procedures were completed, animals were deeply anesthetized
492 with sodium pentobarbital (200 mg/kg) and transcardially perfused with 20ml of
493 phosphate buffer solution (PBS 0.05M) followed by 20ml of paraformaldehyde (PFA 4%).
494 The entire brain and the spinal cord were removed and post-fixed in PFA for 12h. Before
495 slicing, the brain was embedded in a single block of Agar (in PBS, 2%) as well as 3-5mm
496 sections of the spinal cord that were collected in anteroposterior order. Spinal cord and
497 brain sections were sliced at 50 μ m following coronal or sagittal axes and collected in
498 individual well-plates with 300 μ m spacing between consecutive sections. All

499 immunohistochemistry solutions were prepared in a solution of PBS with 0.3% Triton
500 (PBS-Triton). First, sections were blocked in PBS-Triton containing 10% normal donkey
501 serum (NDS, Jackson ImmunoResearch) for 1h at room temperature, following 3-5
502 washes with PBS, sections were transferred in a primary antibody solution containing
503 PBS-Triton, 1% NDS and the corresponding primary antibody. The primary solution was
504 left overnight at 4h under constant gentle shaking. Sections were then washed 3-5 times
505 with PBS before to be transferred to the secondary antibody solution (PBS Triton, 1%
506 NDS, and the corresponding secondary antibody) and kept under constant gentle shaking
507 for 4-5h at room temperature. Sections were then washed 3-5 times in PBS before
508 mounted on microscope slides using a mounting medium (Vectashield) and prepared for
509 imaging. Primary antibodies were as follows: mCherry (used for mRuby, mCherry and
510 TdTomato, made in mouse, monoclonal, ABCAM AB167477, concentration 1:1000),
511 ChAT (choline acetyltransferase, made in goat, polyclonal, Merk Millipore, AB144P,
512 concentration 1:500), GFP (to enhance eYFP detection, made in rabbit, polyclonal
513 already conjugated-488, Thermofisher, A21311, concentration 1:1000) and Fluorogold
514 (made in rabbit, polyclonal, Merck Millipore, AB153-I, concentration 1:1000). Secondary
515 antibodies were as follows: anti-Goat CY3 (raised in donkey, Jackson Immuno-research
516 705-165-147, concentration 1:1000); anti-Goat CY5 (raised in donkey, Jackson Immuno-
517 research 705-175-147, concentration 1:1000), anti-mouse CY3 (raised in donkey,
518 Jackson Immuno-research 715-165-150, concentration 1:1000), anti-rabbit 488 (raised in
519 donkey, Jackson Immuno-research 711-545-152, concentration 1:1000) and anti-rabbit
520 AMCA (raised in donkey, Jackson Immuno-research 711-155-152, concentration
521 1:1000).

522

523 ***Imaging***

524 Fluorescent images were captured using a confocal laser microscope (Olympus
525 FV1000S) with the FluoView software (Olympus), under a dry 10X/0.40 NA objective,
526 20X/0.40NA or an oil-immersion 63X/1.40NA objective. All sections were first acquired at
527 high resolution (10X, 1024 * 1024 pixels) using mosaic reconstruction to determine the
528 virus diffusion, the viral injection site and the placement of the optic fiber. For cell counting,
529 sections were scanned at 20X using medium resolution (1048 * 720). For projections and
530 synapses counting, sections were acquired at high resolution (20X, 2048 *2048 pixels),
531 with a 1µm-optical section z-stack across 40µm (top and bottom 5µm of the section were
532 discarded). Single images of axonal projections or synaptic contacts were acquired at
533 high magnification (63X), high-resolution (2048*2048 pixels), with 4-time deconvolution
534 and a 1µm-optical section z-stack across 40µm. All pictures were saved as images and
535 metadata in order to correct the mosaic alignment using Photoshop (version 5, Adobe).
536 All fluorescent images were transferred to Fiji software, were color-converted based on
537 the secondary antibody and the filter used (AMCA: 400 – 450 nm, Alexa488: 500-550 nm,
538 CY3: 590-620 and CY5: 650-700), signal-adjusted, and merged using in-built tools.

539

540 ***Cell counting***

541 Each brain and spinal cord section scanned were converted into bitmap images,
542 duplicated and overlapped with the outline of the Paxinos and Franklin⁶⁰, mouse brain
543 Atlas (7th edition). Images were then transferred to Fiji, and in-built counting tools were
544 used. The number of cell markers per nucleus (as defined by the Atlas) was then

545 transferred to an Excel spreadsheet. The counted cells of each identified brain structure
546 that were represented in separate sections were put together for the final analysis and
547 normalized to the total number of neurons counted in all brain sections collected for each
548 animal. For RvdG experiments, the YFP-positive neurons located in the site of injection
549 (PPN/CnF) were not quantified for the whole brain mapping. For the spinal cord, a random
550 number of spinal cord sections that were representative of all segments (40-80 sections
551 per mice) were processed and counted. Based on the average number of inputs neurons
552 per section found, we extrapolated the putative number of inputs in the entire spinal cord
553 using an average length of 3.2cm. Normalized data and raw data were tested for normality
554 and compared using a Wilcoxon rank-sum test (non-parametric). The threshold to
555 significance was determined at $P < 0.05$. All data were shown as mean \pm SEM.

556

557 ***Synapse density estimation***

558 Brain sections were prepared as above. The nucleus' outlines were drawn using built-in
559 tools and the number of pixels above the threshold, the surface area, the background
560 gray value, and the average gray value within the drawing area were obtained to define
561 the density of the synapses using the formula:

$$562 \frac{\text{average gray value} - \text{background gray value}}{\text{surface area}}$$

563 The area that was considered as an artifact due to dust or air-bubbles generated during
564 immunohistochemistry or slice mounting was manually discarded using a similar
565 approach. Normalized data and raw data were tested for normality and compared using
566 a Wilcoxon rank-sum test (non-parametric). The threshold to significance was placed at
567 $P < 0.05$. All data were shown as mean \pm SEM.

568

569 ***Ex Vivo Electrophysiology***

570 9-16 days old animals expressing tdTomato fluorescent protein in a VGLUT2-dependent
571 way (n = 25) were used for the slice electrophysiology experiments. Coronal midbrain
572 slices (with 200 μ m thickness) were prepared in low Na⁺ aCSF (cca. 0 - -2 °C) with a
573 Microm HM 650V vibratome (Microm International GmbH, Walldorf, Germany). The slices
574 were incubated in normal aCSF for 1 hour on 37°C prior to starting the experiment. The
575 resistance of the patch pipettes was 5-7 M Ω , and the composition of the internal solution
576 was the following (in mM): K-gluconate, 120; NaCl, 5; 4-(2-hydroxyethyl)-1-
577 piperazineethanesulfonic acid (HEPES), 10; Na²- phosphocreatinine, 10; EGTA, 2;
578 CaCl₂, 0.1; Mg-ATP, 5; Na³-GTP, 0.3; biocytin, 8; pH 7.3. Whole-cell patch-clamp
579 experiments were conducted at room temperature with an Axopatch 200A amplifier
580 (Molecular Devices, Union City, CA, USA). Clampex 10.0 software (Molecular Devices,
581 Union City, CA, USA) was used for data acquisition, while data analysis was performed
582 by Clampfit 10.0 (Molecular Devices) software. Only stable recordings with minimal leak
583 currents were considered, and only recordings with series resistance below 30 M Ω , with
584 less than 10% change, were included. Both voltage- and current clamp configurations
585 were employed. Protocols and recorded parameters are represented in Supplementary
586 Table 1. In certain experiments, 1 μ M tetrodotoxin (TTX; Alomone Laboratories,
587 Jerusalem, Israel) was administered to eliminate action potential generation in the
588 preparation. Visualization of the genetically encoded fluorescent marker (tdTomato) was
589 achieved by using a fluorescent imaging system (Till Photonics GmbH, Gräfeling,
590 Germany) containing a xenon bulb-based Polychrome V light source, a CCD camera

591 (SensiCam, PCO AG, Kelheim, Germany), an imaging control unit (ICU), and the Till
592 Vision software (version 4.0.1.3).

593

594 *Morphological analysis of the recorded neurons:* Patched neurons were labeled with
595 biocytin and samples were fixed (4% paraformaldehyde in 0.1 M phosphate buffer; pH
596 7.4; 4 °C) for morphological identification of the neurons. Tris-buffered saline (in mM, Tris
597 base, 8; Trisma HCl, 42; NaCl, 150; pH 7.4) supplemented with 0.1% Triton X-100 and
598 10% bovine serum (60 min) was used for permeabilization. Incubation was performed in
599 phosphate buffer containing streptavidin-conjugated Alexa488 (1:300; Molecular Probes
600 Inc., Eugene, OR, USA) for 90 min. The cells were visualized using a Zeiss LSM 510
601 confocal microscope (Carl Zeiss AG). The reconstruction of neurons was performed by
602 NeuroLucida software (MBF Bioscience, Williston, VT, USA).

603

604 ***Behavioral Assays***

605 *Laser stimulation:* A blue laser (450nm, OEM Laser system) was used to excite ChR2.
606 Stimulation parameter varied. Several stimulation frequencies were used (1Hz-20z) and
607 controlled by a low-noise shutter (SH1, Thorlabs) plugged to the control cube (KSC101,
608 Thorlabs) which in turn was triggered by TTL signals delivered by the Anymaze interface.
609 The laser output was set to be 2-3 mW at the end of the patchcord.

610

611 *Small Open field:* Following implantation of the optic fiber, animals were allowed to
612 recover for 5 to 7 days. Animals were then habituated for 5 minutes to the open field
613 before testing. The custom-made open field was developed as following: a dark cube of

614 40 x 40 x 40 cm with the floor covered with a non-reflective white surface to allow better
615 contrast between the background and the mouse, 4 white lamps were positioned on the
616 top of the cage to allow optimal illumination. Animals were tested for 30 minutes, with
617 optogenetic stimulation 1s ON/9s OFF (20ms pulses, <3mW laser power) using
618 stimulation frequencies of 1, 10 or 20Hz. The animal movements were recorded using a
619 high-speed/high-resolution camera (120fps) RunCam2 and the software Anymaze
620 (Stoelting). The software was tracking the gravity center (body) of the animal, the head
621 and the tail position. The time in the center (15cm circle located in the center of the field)
622 or periphery was defined based on the position of the animal body. The software recorded
623 the animals' speed, distance traveled, time in center and time in the periphery. Whilst
624 online analyses of the above-mentioned parameters were based on 30 recorded frames
625 per second, offline analyses used 120 frames per second. On- and offline analyses were
626 compared and sequences differing in more than 5% were discarded. Stimulation delivery
627 was controlled using the software interface Ami1.

628

629 *Large open field:* The above experiment was repeated in a larger open field, which
630 consisted of a dark cube of 80 x 80 x 80 cm with the same features as the one described
631 above. A small slope was built at the base of each wall to avoid animals making contact
632 with the walls. Animals were tested for 60 minutes, optogenetic stimulations were
633 delivered for 1 minute (repeated loops of 1s ON/9s OFF on) and were spaced by 1 minute
634 with no stimulation. Stimulation protocol was as follow: 20ms pulses, <3mW laser power
635 and the frequency was increased from 0.1 to 30 Hz (0.1, 0.5, 1, 2.5, 5, 7.5, 10, 12.5, 15,
636 17.5, 20, 22.5, 25, 27.5, 30). Animals movement were recorded and analyzed as above.

637

638

639 *Treadmill:* The treadmill apparatus consists of a custom-made belt of 10cm by 30cm that
640 is operated at constant speed. The animals' position, the center of the body, head, and
641 tail were monitored using the Anymaze software via a high-speed camera (RunCam2)
642 camera placed above the treadmill. Further, the behavior was also monitored using a
643 camera located on the side of the treadmill. Animals were tested for 15 minutes while
644 receiving optogenetic stimulation (1s ON/9s OFF, 20ms pulses, <3mW, 10Hz). 2 days
645 before testing, animals were habituated to the still treadmill for 10 minutes. One day
646 before testing, the habituation occurred on the moving treadmill. On the day of testing,
647 animals were connected to the laser and placed on the treadmill with the speed set at 3m
648 per minute. Animals were tracked and analyzed to determine distance traveled, average
649 speed and position of the head-body and tail-body axes. Stimulation delivery was
650 controlled using the software interface Ami1.

651

652 *Elevated grid:* The elevated grid apparatus consists of a custom made 60 x 30 cm grid
653 (1.5 x 1.5 cm grid space), elevated 1m off the floor and illuminated from the bottom. The
654 animals' behavior was monitored by two high speed-cameras located on the side (for
655 rearing and foot slips) and on the bottom (for the animal position). Animals were not
656 exposed to the apparatus before testing to avoid any habituation, but all animals were
657 handled for several days before testing. On the day of the testing, animals were
658 connected to the laser, placed in the middle of the grid and their behavior was monitored
659 for 20min using Anymaze software while receiving optogenetic stimulation for 1s every

660 9s (20ms pulses, <3mW, 10Hz). Animals were tracked and analyzed to determine
661 distance traveled, average speed and position of the head-body and tail-body axes.
662 Stimulation delivery was controlled using the software interface Ami1.

663

664 *Control animals:* For each experiment, control animals consisted of WT animals receiving
665 the same manipulations and undergoing the same procedures as the experimental
666 groups. Control animals were excluded if the injection was “out-of-target” or the
667 implantation was not correctly positioned.

668

669 *High-resolution analyses:* The cartesian coordinates of each acquired frame (120 fps)
670 were converted offline into interframe distance traveled. The peristimulation distance
671 traveled was defined as the “stimulation locked distance traveled” using z-score
672 transformation normalized into the 5s baseline prior to each stimulation. Due to camera
673 fps variability, the cartesian coordinates were used at 5ms intervals by extrapolating the
674 interframe position.

675

676 *Data analyses:* All experiments were randomly organized, and data of each animal were
677 analyzed similarly. To prevent data loss during animal tracking, the data from online and
678 offline were compared, and the portion of data was removed if we found any differences
679 in the recording. Following comparison of the online/offline tracking, data were expressed
680 as the following parameters: overall distance traveled, average speed during the entire
681 session, number of ipsilateral of contralateral rotation and distance traveled 5 seconds
682 before and after each stimulation (with 5ms bin size). High-resolution data were converted

683 to z-score of the distance traveled compared to the baseline (-5 to 0s before stimulation).
684 All data were compared between groups using one-way ANOVA or by comparing the
685 frequency of stimulation and groups using multivariate ANOVA. A significant ANOVA
686 effect was compared using Bonferroni posthoc analyses.

687

688 ***Electromyogram recordings***

689 During a surgical procedure as described above, an incision was made at the neck,
690 forelimbs and hindlimbs of the animals and muscles were exposed. EMG bipolar
691 electrodes were implanted in the biceps brachia and biceps femoris of the ipsilateral and
692 contralateral limbs and the connector was affixed on the skull of the animals. In addition,
693 an optic fiber (flat-cut, 200 μ m, 0.50NA) was implanted above the PPN or CnF (300 μ m
694 above the injection site) following viral injections and maintained in position using anchor
695 screws. EMG signals were converted into RMS signal and each trial was analyzed
696 individually. All animals received same number of stimulation to avoid overrepresentation.

697

698 ***Histological verification***

699 Following staining of sections located on in the vicinity of the injection sites for GFP and
700 ChAT, high-resolution images were acquired and processed using Fiji. All ChAT-positive
701 neurons located at the border of the PPN were labeled using in-built tools, then all YFP-
702 positive cell bodies were labeled and their location recorded. The number of YFP-positive
703 neurons located further than 100 μ m from the closest ChAT-positive neurons (for PPN
704 and the ventral border of the CnF), or within the colliculus (for the dorsal border of the
705 CnF) was calculated as a percentage of the total number of neurons within the injection

706 site. If more than 5% of YFP-positive neurons were located further than 100 μ m (for PPN)
707 or closest to 100 μ m or inside the colliculus (for CnF) the animal was excluded from further
708 analyses.

709

710 ***Statistical Analyses***

711 Anatomical, in vitro and in vivo data (including behavioral data) are represented as
712 mean \pm SEM. No power analyses were conducted prior to the experiments and group sizes
713 were determined following comparable previously published experiments. Anatomical
714 data was compared using the Wilcoxon rank-sum test following prior determination of the
715 violation of the assumption of normality of the data. In vitro data was analyzed using
716 Student's t-test, one-way ANOVA or mixed ANOVA. One way ANOVAs and MANOVAs
717 were conducted for in vivo and behavioral experiments. All ANOVAs were followed by
718 Bonferroni corrected post-hoc tests. Level of significance was set at $p < 0.05$.

719

720 ***Data Availability***

721 All custom script, unprocessed figures, whole-brain scans, recordings data are available
722 under reasonable requests.

723

724 **Figure Legends**

725 **Figure 1. Segregation of MLR structures by viral transduction.**

726 Viral injection volume was adjusted to be restricted within the border of the PPN (**A**) or
727 the CnF (**B**) using as a marker the expression of choline acetyltransferase (ChAT; 100 μ m
728 radius). The dorsal and ventral border of the PPN was defined as 100 μ m distance from

729 the outer cholinergic neuron soma (**A**), whereas the ventral border of CnF was 100 μ m
730 further from cholinergic neurons (**B**).

731

732 **Figure 2. Axonal distribution of PPN and CnF glutamatergic neurons.**

733 **A-B**, Following injection of AAV-DIO-GFP-2A-synaptophysin-mRuby (**A**) restrained to the
734 PPN (**A1**) or the CnF (**A2**) borders, we observed widespread distribution of GFP-labeled
735 axons (**B**). **C-D**, Quantification of the total count of GFP-positive soma (PPN: 504.66 \pm
736 58.42; CnF: 518.33 \pm 54.67, one-way ANOVA $F_{(1,5)} = 0.03$, $P = 0.87$) and overall synaptic
737 density (PPN: 0.27 \pm 0.024 pixels/100 μ m²; CnF: 0.18 \pm 0.02 pixels/100 μ m², one-way
738 ANOVA $F_{(1,86)} = 7.64$, $P = 0.007$). **E**, Segregated synaptophysin labeling across the brain
739 revealed distinct patterns of innervation by PPN and CnF glutamatergic neurons,
740 particularly in the basal ganglia, forebrain, thalamus, midbrain, medulla and cerebellum
741 (Wilcoxon test). **F**, Fluorescent micrographs illustrating GFP and synaptophysin labeling
742 in the striatum following PPN transduction. **G**, Distribution of axons in the brainstem
743 following PPN and CnF injections. **J**, Synaptic distribution in a cervical segment of the
744 spinal cord. **K**, Axonal reconstructions in typical examples of cervical, thoracic, lumbar,
745 and sacral spinal cord segments following unilateral PPN injection. * $P < 0.05$. All
746 experiments have been replicated at least 3 times. Single data are represented by small
747 dots. All data are represented as mean \pm SEM.

748

749 **Figure 3. Whole-brain inputs to PPN and CnF glutamatergic neurons.**

750 **A-D**, Following injection of helpers and rabies virus in the PPN (**A**) and the CnF (**B**), we
751 quantified the number of starter neurons (**C**, PPN: 145.33 \pm 40.19, CnF: 74.66 \pm 24.91, t-

752 test $t_{(4)} = 1.49$, $P = 0.21047$) and the number of inputs neurons across all brain areas (**D**,
753 raw: PPN: 708.91 ± 242.25 , CnF: 143.33 ± 12.17 , t-test $t_{(4)} = 2.33$, $P = 0.0401$; normalized:
754 PPN: 4.73 ± 1.27 , CnF: 2.28 ± 0.94 input/starter, Mann-Whitney: $Z = 1.964$, $P = 0.0495$).
755 **E-K**, Fluorescent micrographs of representative areas where inputs neurons were
756 identified, including the dorsal brainstem (**E**) and the pons (**H**) following a CnF injection,
757 and the ventral midbrain (**F-G**), the striatum (**I**), the cortex (**J**) and the spinal cord (**K**)
758 following a PPN injection. **L**, Quantification of the number of inputs neurons projecting to
759 PPN (blue) and CnF(green) glutamatergic neurons for each brain area normalized by the
760 overall total number of input neurons per animal (Wilcoxon test). * $P < 0.05$. All experiments
761 have been replicated at least 3 times. Single data are represented by small dots. All data
762 are represented as mean \pm SEM.

763

764 **Figure 4. Functional and morphological differences of PPN and CnF glutamatergic**
765 **neurons.**

766 **A-B**, Fluorescent micrographs of PPN and CnF glutamatergic neurons obtained from
767 VGLUT2-tdTomato mice following biocytin labelling. **C-D**, Reconstruction of
768 representative glutamatergic neurons in the PPN (**C**) and the CnF (**D**), which were
769 subsequently used to quantify the number of proximal dendrites, nodes and endings
770 (**Supplementary Table 2**). **E-G**, Changes of spike frequency adaptation by increasing
771 depolarizing steps revealed functional subtypes of glutamatergic neurons defined as
772 follows, (**E**) 'non-adapting': less than 50% increase in the adaptation index of the action
773 potential trains obtained with 50 and 120 pA current injections; (**F**) 'slowly-adapting': more
774 than 50% change of the adaptation index but fired during the whole 1-s-long depolarizing

775 step; and **(G)** ‘rapidly-adapting’: paused firing after application of greater depolarizing
776 steps. **H**, Proportion of neurons with different spike frequency adaptation properties in
777 the PPN and the CnF. **I-J**, Voltage traces from glutamatergic neurons in the PPN (**I**) and
778 the CnF (**J**) representing high threshold oscillations during 120 pA depolarizing square
779 current injections under control conditions (left) and following TTX application (right; red
780 squares of the small inserts indicate the magnified area). Related power spectra are
781 displayed on the left (average \pm SEM; PPN control, black circles; PPN+TTX, gray circles
782 with black contours; CnF control, red circles; CnF+TTX, gray circles with red contours).
783 **K-L**, Representative current traces from neurons in the PPN (**K**) and the CnF (**L**) elicited
784 by voltage ramp injections under control conditions (black) and with TTX (gray; left). TTX-
785 sensitive currents shown on the right panels (PPN, blue; CnF, green). Scale bars: A-B:
786 0.5mm, C-D: 50 μ m. * $P < 0.05$. All experiments have been replicated at least 3 times.
787 Group value and statistics are provided in Table 2. All data are represented as mean \pm
788 SEM.

789

790 **Figure 5. Locomotor effects following stimulation of PPN and CnF glutamatergic**
791 **neurons.**

792 **A**, Trace examples of control, PPN, and CnF stimulated animals tested in the open field.
793 Red circle represents the center of the arena. The behavior was recorded at a resolution
794 of 30 frame-per-second. **B-C**, Normalized distance traveled (5ms bin) during individual
795 10Hz stimulation of CnF (**B**) or PPN (**D**) glutamatergic neurons; control animals (gray;
796 wild-type) received the same experimental treatment (two-way MANOVA groups \times
797 stimulation; group effect $F(2,491)=198.21$, $P=0.00001$, stimulation effect

798 $F(2,491)=503.43$, $P=0.00001$, interaction effect $F(4,491)=201.55$, $P=0.00001$; posthoc
799 Bonferroni, $P_{\text{CNFstim_PPNstim}}=0.0001$, $P_{\text{CNFstim_CTRLstim}}=0.0001$, $P_{\text{PPNstim_CTRLstim}}=0.0001$). The
800 line above represents the statistical difference of the distance traveled compared to the
801 baseline (1s). **D-E**, Distance traveled per 5ms bin during individual stimulation of CnF (**D**)
802 or PPN (**E**) glutamatergic neurons during resting (black) or during spontaneous
803 movement (3-way mixed ANOVA structure x state x stimulation: stim effect $F(2,443)=9$,
804 $P=0.0001$; structure: $F(1,443)=79.95$, $P=0.00001$, state: $F(1,443)=2792.70$, $P=0.00001$,
805 interaction: $F(4,443)=30.72$, $P=0.00001$, posthoc Bonferroni $P_{\text{PPN_mobile_immobile}} = 0.0001$;
806 $P_{\text{cnf_mobile_immobile}} > 0.05$). The line above represents the statistical difference of the distance
807 traveled compared to the baseline (1s). **F-G**, Total distance traveled and average speed
808 (in m/s) following stimulation at 1Hz, 10Hz or 20Hz (20ms pulse; distance traveled: two-
809 way RM-ANOVA: $F_{\text{group}}(2,62)=0.86$, $P=0.433$, $F_{\text{frequency}}(2,62)=5.22$, $P=0.0102$,
810 $F_{\text{interaction}}(4,62)=6.83$, $P=0.0003$, post hoc: 1Hz: $P_{\text{ctrl-CNF}}=0.256$, $P_{\text{ctrl-PPN}}=0.11$; 10Hz: $P_{\text{ctrl-}}$
811 $\text{CNF}=0.002$, $P_{\text{ctrl-PPN}}=0.25$; 20Hz: $P_{\text{ctrl-CNF}}=0.002$, $P_{\text{ctrl-PPN}}=0.035$; average speed:
812 $F_{\text{group}}(2,62)=2.71$, $P=0.1046$, $F_{\text{frequency}}(2,62)=1.93$, $P=0.16$, $F_{\text{interaction}}(4,62)=5.55$,
813 $P=0.0014$, post hoc: 1Hz: $P_{\text{ctrl-CNF}}=0.11$, $P_{\text{ctrl-PPN}}=0.14$; 10Hz: $P_{\text{ctrl-CNF}}=0.008$, $P_{\text{ctrl-}}$
814 $\text{PPN}=0.25$; 20Hz: $P_{\text{ctrl-CNF}}=0.007$, $P_{\text{ctrl-PPN}}=0.031$). **H**, Percentage of time spent in the center
815 of the arena ($F(2,20)=0.30$, $P=0.7426$). **I**, Representative traces of PPN and CnF
816 stimulated animals on the constant-speed treadmill. **J-K**, Distance traveled and average
817 distance from the front of the treadmill following stimulation at 10Hz (distance traveled:
818 one way ANOVA $F(2,21)=24.03$, $P=0.00001$, Bonferroni $P_{\text{PPN_CTRL}}=1.0$,
819 $P_{\text{CTRL_CNF}}=0.0001$, $P_{\text{PPN_CNF}}=0.0001$; average speed: $F(2,21)=17.41$, $P=0.0001$,
820 Bonferroni $P_{\text{PPN_CTRL}}=0.714$, $P_{\text{CTRL_CNF}}=0.0001$, $P_{\text{PPN_CNF}}=0.001$; distance to the front:

821 (F(2,21)=14.44, P=0.0001, Bonferonni $P_{PPN_CTRL}=0.0001$, $P_{CTRL_CNF}=0.715$,
822 $P_{PPN_CNF}=0.001$). * P<0.05. All experiments have been replicated at least 3 times. Whisker
823 plot are representing mean, median, standard error and 25/75th percentile. All data are
824 represented as mean \pm SEM.

825

826 **Figure 6. Modulation of gait by PPN glutamatergic neurons.**

827 **A**, Representation of the elevated grid walk test. **B**, Representative traces in control and
828 PPN groups (CnF group is not shown, see text for details). **C-D**, Distance traveled (t-test
829 two-tail t(28)=7.8146, P=0.00001) and average distance to the center (t(28)=6.34, P=
830 0.00001) following 10Hz stimulation. **E**, Representative images of mice making footslips
831 during the elevated grid-walk test. **F**, The total number of footslips (t(15)=5.29,
832 P=0.00001). * P<0.05. All experiments have been replicated at least 3 times. Whisker plot
833 are representing mean, average, standard error and 25/75th

834

835 **Figure 7. Differential involvement of PPN and CnF glutamatergic neurons in muscle**
836 **tone generation.**

837 **A**, Example of electromyogram (EMG) activity recorded at the level of the biceps following
838 laser stimulation and the conversion into root-mean-square (RMS). **B**, Raw amplitude
839 (μ V) of the RMS-EMG of ipsilateral forelimb biceps during baseline, immediately or 500
840 ms after single stimulation pulses delivered in the PPN, CnF or sham (0-0.5s after
841 stimulation: one-way ANOVA F(2,214)=5.59, P = 0.0001, post hoc Bonferroni
842 $P_{PPN_vs_CTRL}=0.004$, $P_{CNF_vs_CTRL}=0.004$, $P_{PPN_vs_CNF}=1.0$; 0.5 to 2s after stimulation:
843 F(2,214)=46.62, P=0.00001, post hoc Bonferroni $P_{PPN_vs_CTRL}=0.0001$,

844 $P_{\text{CNF_vs_CTRL}}=0.0001$, $P_{\text{PPN_vs_CNF}}=0.001$). **C**, Change in the RMS signal following repeated
845 single stimulation pulses recorded at the level of the biceps (% change relative to 1s
846 baseline: PPN: $178.60 \pm 10.06\%$, CNF: $115.72 \pm 3.93\%$, CTRL: $94.33 \pm 4.55\%$, one-Way
847 ANOVA $F(2,214)=26.26$, $P=0.00001$; Post hoc Bonferroni $P_{\text{PPN-CN}}=0.0001$, $P_{\text{PPN-}}$
848 $\text{CTRL}=0.0001$, $P_{\text{CNF-CTRL}}=0.804$). **D**, Response latency and duration of the significant
849 increase in the RMS signal in response to PPN or CnF stimulation (latency:
850 $F(1,212)=6.44$, $P = 0.019$; duration: $F(1,212)=19.29$, $P=0.00001$). **E-F**, Change in the
851 RMS signal in the ipsilateral and contralateral forelimbs biceps following stimulation in
852 PPN ($\text{PPN}_{\text{ispi}}=218.08 \pm 17.02\%$, $\text{PPN}_{\text{contra}} 138.46 \pm 5.71\%$, Two-Way ANOVA stim x side:
853 $F_{\text{stim}}(1,401)=648.221$, $P=0.00001$, $F_{\text{side}}(1,401)=39.6$, $P=0.0001$, $F_{\text{interaction}}=242.6$,
854 $P=0.00001$) and CnF groups ($\text{CnF}_{\text{ispi}}: 117.06 \pm 5.54\%$, $\text{CnF}_{\text{contra}}: 113.55 \pm 5.51\%$, two-Way
855 ANOVA stim x side: $F_{\text{stim}}(1,401)=51.29$, $P=0.00001$, $F_{\text{side}}(1,401)=1.80$, $P=0.18$,
856 $F_{\text{interaction}}(3,401)=18.30$, $P=0.0000$). Lines represent statistical difference compared to
857 baseline. * $P<0.05$. All experiments have been replicated at least 3 times. Whisker plot
858 are representing mean, median, standard error and 25/75th percentile; individual data are
859 represented by small dots. Out of range data points are reported as numbers above the
860 histogram. All data are represented as mean \pm SEM.

861

862

863

864 **Supplementary material**

865 **Supplementary Figure 1. Histological analysis. Related to Figures 2, 3, 5 and 6.**

866 **A**, Virus spread (circles) and locations of the tip of the optic fibers (red circle) for PPN
867 (green) and CnF (blue) groups. **B**, Fluorescent micrographs of PPN glutamatergic
868 neurons expressing GFP and synaptophysin. **C**, High-resolution images of a transduced
869 CnF glutamatergic axon in PAG expressing GFP in the shaft and boutons and
870 synaptophysin-mRuby in the terminals.

871

872 **Supplementary Figure 2. Input/output relationship of PPN and CnF. Related to**
873 **Figures 2 and 3.**

874 **A**, Schematic summary of PPN (blue) and CnF glutamatergic (green) axonal distribution
875 using relative synaptic density. **B**, Schematic summary of PPN (blue) and CnF
876 glutamatergic (green) neuron inputs. **C-D**, Graphical representation of inputs and outputs
877 of PPN and CnF glutamatergic neurons based on the data presented in Figures 2 and 3.
878 Input arrows (left) are defined based on the normalized distribution of inputs neurons.
879 Output arrows (right) are defined based on the normalized distribution of the synapses.

880

881 **Supplementary Figure 3. Membrane properties of the PPN and CnF glutamatergic**
882 **neurons. Related to Figure 4.**

883 **A**, A-current was observed on most PPN and CnF glutamatergic neurons. Current traces
884 elicited by +20 mV voltage step, preceded by -120 mV (black) and -10 mV (red) voltage
885 steps (example shows PPN). The left current trace is the difference of the black and red

886 current traces. **B-D**, Representative examples of the firing properties of PPN
887 glutamatergic neurons. Trains of action potentials elicited by 100 pA depolarizing current
888 injection from -59 mV (**B**), -87 mV (**C**) and -73 mV resting membrane potential (**D**, in the
889 presence of TTX; the arrow indicates the lack of delay). **E-I**, Depolarization and action
890 potential firing elicited by 30 pA depolarizing square current injection from -66 mV (**E**) and
891 -83 mV (**F**) resting membrane potentials. Note the low threshold depolarizing spike (black
892 arrow). (**G**) 30 pA hyperpolarizing current injection from -53 mV resting membrane
893 potential revealed rebound spike and firing (black arrow). **H-I**, Low threshold spike and
894 rebound depolarizing spike (respectively; arrow) in the presence of TTX. **J**, Distributions
895 of functional neuronal types in the PPN and CnF. Group I neurons display low threshold
896 depolarizing spikes but lack A-current (PPN: 22.7%, CnF 33.3%). Group II neurons
897 display A-current (PPN: 47.7%, CnF 37.5%). Group III neurons display both (PPN: 9.1%,
898 CnF 16.6%). Group IIIK lacks all (PPN: 20.5%, CnF 12.5%). **K**, Proportion of PPN and
899 CnF neurons displaying A-current. **L**, Proportion of PPN and CnF neurons displaying low
900 threshold spikes (LTS). All experiments have been replicated at least 3 times. All data are
901 represented as mean \pm SEM.

902

903 **Supplementary Figure 4. Physiological properties of MLR glutamatergic neurons.**

904 **Related to Figure 4.**

905 Statistical summary of the number of action potentials elicited by 1-s depolarizing step,
906 the adaptation index, the ratio of the amplitude of the last and first action potentials of the
907 train, the ratio of the width of the last and first action potentials of the train, the frequency
908 and the duration of the train in different functional subgroups (non-adapting, red; slowly

909 adapting, purple; rapidly adapting, black). The significance was calculated between the
910 first and last datapoints within each trace. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$. All
911 experiments have been replicated at least 3 times. All data are represented as mean \pm
912 SEM.

913

914 **Supplementary Figure 5. Frequency-dependent modulation of locomotion in the**
915 **CnF. Related to Figures 5 and 6.**

916 **A-B**, Distance traveled following optogenetic stimulation (1s ON/9s OFF) during and
917 immediately after optogenetic stimulation of CnF glutamatergic neurons using a
918 randomized stimulation protocol ranging from 0.1Hz to 30 Hz (mixed ANOVA; *during*:
919 $F(14,89)=2.69$, $P=0.003$, trendline: $R^2 = 0.4774$, Max: 12.5, Posthoc Bonferroni $P=0.034$;
920 *after*: $F(14,89)=1.24$, $P=0.2994$). Gray dots represent individual data points, black dots
921 represents average values, vertical lines represent SEM, and the red line represents the
922 best fitted trendline ($y=-0.0314x^2+0.7389x+4.9582$). **C**, Average speed of animals in the
923 CnF (blue), PPN (green) and control groups (gray) during the treadmill test
924 ($F(2,21)=17.41$, $P=0.0001$, Bonferonni posthoc $P_{PPN_CTRL}=0.714$, $P_{CTRL_CNF}=0.0001$,
925 $P_{PPN_CNF}=0.001$). **D**, Average speed of mice in the PPN (green) and control groups (gray)
926 during the elevated grid walk test (t-test two tail: $t(28)=6.39$, $P=0.00001$,). **E**, Total number
927 of rearing events observed in the elevated grid walk test following stimulation of PPN
928 glutamatergic neurons (green) and compared to control mice (gray; $t(15)=2.63$,
929 $P=0.0095$).

930

931 **Supplementary Figure 6. Complementary EMG experiments. Related to Figure 7.**

932 **A**, Z-score and % change in the RMS signal in the ipsilateral and contralateral biceps
933 activity following stimulation of control animals (sham; CTRL_{Lipsi}: 97.45±6.09%, CTRL_{contra}:
934 92.33±6.17, two-Way ANOVA stim x side: F_{stim}(1,401)=0.18, P=0.67,
935 F_{side}(1,401)=3.12, P=0.078, F_{interaction}(3,401)=18.30, P=0.093). **B-C**, Response
936 latency (two-way ANOVA target x side: F_{target}(1,206)=14.24, P=0.0002, F_{side}(1,206)=0.14,
937 P=0.71, F_{interaction}(1,206)=0.05, P=0.82) and response duration (two-way ANOVA target x
938 side: F_{target}(1,212)=371.60, P=0.00001, F_{side}(1,212)=0.52, P=0.47, F_{interaction}(1,212)=1.39,
939 P=0.23) of the change in muscle activity following stimulation of PPN or CnF
940 glutamatergic neurons (ipsilateral vs contralateral biceps).

941

942 **Table 1. Abbreviation of major structures reported in the manuscript.**

943

944 **Table 2. Morphological and functional parameters of PPN and CnF glutamatergic**
945 **neurons. Related to Figure 4.**

946

947 **Table 3. Percentages of functional subtypes of PPN and CnF glutamatergic neurons.**
948 **Related to Figure 4.**

949

950 **Video 1. Frequency-dependent modulation of locomotion in the CnF. Related to**
951 **Figure 5 and Supplementary Figure 4.** Example of a VGLUT2-cre mice injected in the

952 CnF with AAV-DIO-ChR2-YFP and tested in a large open field using a progressive
953 stimulation protocol ranging from 0.1Hz to 30 Hz.

954

955 **Video 2. Modulation of gait by PPN neurons. Related to Figure 6 and Supplementary**

956 **Figure 4.** Example of a VGLUT2-cre mice injected in the PPN with AAV-DIO-ChR2-YFP

957 and optogenetically stimulated during the elevated grid walk test.

958

959 **Video 3. Activation of locomotor muscles following CnF stimulation. Related to**

960 **Figure 7 and Supplementary Figure 5.** Example of a VGLUT2-cre mice injected in the

961 CnF with AAV-DIO-ChR2-YFP receiving optogenetic stimulation (1 and 5Hz) while held

962 in a tail-lifted position.

963

964

965

966

967

968

969 **References**

- 970 1. Capelli P, Pivetta C, Esposito MS, Arber S. Locomotor speed control circuits in
971 the caudal brainstem. *Nature*. 2017. doi:10.1038/nature24064
- 972 2. Kim LH, Sharma S, Sharples SA, Mayr KA, Kwok CHT, Whelan PJ. Integration of
973 descending command systems for the generation of context-specific locomotor
974 behaviors. *Front Neurosci*. 2017. doi:10.3389/fnins.2017.00581
- 975 3. Garcia-Rill E, Skinner RD, Fitzgerald JA. Activity in the mesencephalic locomotor
976 region during locomotion. *Exp Neurol*. 1983. doi:10.1016/0014-4886(83)90084-5
- 977 4. Shik ML, Severin F V, Orlovskii GN. [Control of walking and running by means of
978 electric stimulation of the midbrain]. *Biofizika*. 1966;11(4):659-666.
- 979 5. Garcia-Rill E, Houser CR, Skinner RD, Smith W, Woodward DJ. Locomotion-
980 inducing sites in the vicinity of the pedunculopontine nucleus. *Brain Res Bull*.
981 1987. doi:10.1016/0361-9230(87)90208-5
- 982 6. Roseberry TK, Lee AM, Lalive AL, Wilbrecht L, Bonci A, Kreitzer AC. Cell-Type-
983 Specific Control of Brainstem Locomotor Circuits by Basal Ganglia. *Cell*. 2016.
984 doi:10.1016/j.cell.2015.12.037
- 985 7. Caggiano V, Leiras R, Goñi-Erro H, et al. Midbrain circuits that set locomotor
986 speed and gait selection. *Nature*. 2018. doi:10.1038/nature25448
- 987 8. Martinez-Gonzalez C, Wang HL, Micklem BR, Bolam JP, Mena-Segovia J.
988 Subpopulations of cholinergic, GABAergic and glutamatergic neurons in the
989 pedunculopontine nucleus contain calcium-binding proteins and are

- 990 heterogeneously distributed. *Eur J Neurosci.* 2012. doi:10.1111/j.1460-
991 9568.2012.08002.x
- 992 9. Wang HL, Morales M. Pedunculo pontine and laterodorsal tegmental nuclei
993 contain distinct populations of cholinergic, glutamatergic and GABAergic neurons
994 in the rat. *Eur J Neurosci.* 2009. doi:10.1111/j.1460-9568.2008.06576.x
- 995 10. Pahapill PA. The pedunculo pontine nucleus and Parkinson's disease. *Brain.*
996 2000. doi:10.1093/brain/123.9.1767
- 997 11. Lau B, Welter ML, Belaid H, et al. The integrative role of the pedunculo pontine
998 nucleus in human gait. *Brain.* 2015. doi:10.1093/brain/awv047
- 999 12. Josset N, Roussel M, Lemieux M, Lafrance-Zoubga D, Rastqar A, Bretzner F.
1000 Distinct Contributions of Mesencephalic Locomotor Region Nuclei to Locomotor
1001 Control in the Freely Behaving Mouse. *Curr Biol.* 2018.
1002 doi:10.1016/j.cub.2018.02.007
- 1003 13. Pahapill PA, Lozano AM. The pedunculo pontine nucleus and Parkinson's
1004 disease. *Brain.* 2000;123(Pt 9):1767-1783.
- 1005 14. Hirsch EC, Graybiel AM, Duyckaerts C, Javoy-Agid F. Neuronal loss in the
1006 pedunculo pontine tegmental nucleus in Parkinson disease and in progressive
1007 supranuclear palsy. *Proc Natl Acad Sci U S A.* 1987.
1008 doi:10.1073/pnas.84.16.5976
- 1009 15. Zweig RM, Jankel WR, Hedreen JC, Mayeux R, Price DL. The pedunculo pontine
1010 nucleus in Parkinson's disease. *Ann Neurol.* 1989. doi:10.1002/ana.410260106

- 1011 16. Zweig RM, Whitehouse PJ, Casanova MF, Walker LC, Januarykel WR, Price DL.
1012 Loss of pedunculopontine neurons in progressive supranuclear palsy. *Ann Neurol*.
1013 1987. doi:10.1002/ana.410220107
- 1014 17. Jellinger K. The pedunculopontine nucleus in Parkinson's disease, progressive
1015 supranuclear palsy and Alzheimer's disease. *J Neurol Neurosurg Psychiatry*.
1016 1988. doi:10.1136/jnnp.51.4.540
- 1017 18. Manaye KF, Zweig R, Wu D, et al. Quantification of cholinergic and select non-
1018 cholinergic mesopontine neuronal populations in the human brain. *Neuroscience*.
1019 1999. doi:10.1016/S0306-4522(98)00380-7
- 1020 19. Hepp DH, Ruitter AM, Galis Y, et al. Pedunculopontine cholinergic cell loss in
1021 hallucinating Parkinson disease patients but not in dementia with Lewy bodies
1022 patients. *J Neuropathol Exp Neurol*. 2013. doi:10.1097/NEN.0000000000000014
- 1023 20. Nandi D. Reversal of akinesia in experimental parkinsonism by GABA antagonist
1024 microinjections in the pedunculopontine nucleus. *Brain*. 2002.
1025 doi:10.1093/brain/awf259
- 1026 21. Jenkinson N, Nandi D, Miall RC, Stein JF, Aziz TZ. Pedunculopontine nucleus
1027 stimulation improves akinesia in a Parkinsonian monkey. *Neuroreport*. 2004.
1028 doi:10.1097/00001756-200412030-00012
- 1029 22. Perera T, Tan JL, Cole MH, et al. Balance control systems in Parkinson's disease
1030 and the impact of pedunculopontine area stimulation. *Brain*. 2018.
1031 doi:10.1093/brain/awy216

- 1032 23. Goetz L, Bhattacharjee M, Ferraye MU, et al. Deep Brain Stimulation of the
1033 Pedunclopontine Nucleus Area in Parkinson Disease: MRI-Based
1034 Anatomoclinical Correlations and Optimal Target. *Clin Neurosurg.* 2019.
1035 doi:10.1093/neuros/nyy151
- 1036 24. Roš H, Magill PJ, Moss J, Bolam JP, Mena-Segovia J. Distinct types of non-
1037 cholinergic pedunclopontine neurons are differentially modulated during global
1038 brain states. *Neuroscience.* 2010. doi:10.1016/j.neuroscience.2010.06.068
- 1039 25. Petzold A, Valencia M, Pál B, Mena-Segovia J. Decoding brain state transitions in
1040 the pedunclopontine nucleus: Cooperative phasic and tonic mechanisms. *Front*
1041 *Neural Circuits.* 2015. doi:10.3389/fncir.2015.00068
- 1042 26. Sherman D, Fuller PM, Marcus J, et al. Anatomical location of the mesencephalic
1043 locomotor region and its possible role in locomotion, posture, cataplexy, and
1044 Parkinsonism. *Front Neurol.* 2015. doi:10.3389/fneur.2015.00140
- 1045 27. Mori S, Shik ML, Yagodnitsyn AS. Role of pontine tegmentum for locomotor
1046 control in mesencephalic cat. *J Neurophysiol.* 1977. doi:10.1152/jn.1977.40.2.284
- 1047 28. Nieuwenhuys R, Puelles L. *Towards a New Neuromorphology.*; 2015.
1048 doi:10.1007/978-3-319-25693-1
- 1049 29. Puelles L. Survey of midbrain, diencephalon, and hypothalamus neuroanatomic
1050 terms whose prosomeric definition conflicts with columnar tradition. *Front*
1051 *Neuroanat.* 2019. doi:10.3389/fnana.2019.00020
- 1052 30. Korte SM, Jaarsma D, Luiten PGM, Bohus B. Mesencephalic cuneiform nucleus

1053 and its ascending and descending projections serve stress-related cardiovascular
1054 responses in the rat. *J Auton Nerv Syst.* 1992. doi:10.1016/0165-1838(92)90137-
1055 6

1056 31. Futami T, Takakusaki K, Kitai ST. Glutamatergic and cholinergic inputs from the
1057 pedunculo pontine tegmental nucleus to dopamine neurons in the substantia nigra
1058 pars compacta. *Neurosci Res.* 1995. doi:10.1016/0168-0102(94)00869-H

1059 32. Lavoie B, Parent A. Pedunculo pontine nucleus in the squirrel monkey: Cholinergic
1060 and glutamatergic projections to the substantia nigra. *J Comp Neurol.* 1994.
1061 doi:10.1002/cne.903440205

1062 33. Assous M, Dautan D, Tepper JM, Mena-Segovia J. Pedunculo pontine
1063 glutamatergic neurons provide a novel source of feedforward inhibition in the
1064 striatum by selectively targeting interneurons. *J Neurosci.* 2019.
1065 doi:10.1523/JNEUROSCI.2913-18.2019

1066 34. Bajic D, Proudfit HK. Projections from the rat cuneiform nucleus to the A7, A6
1067 (locus coeruleus), and A5 pontine noradrenergic cell groups. *J Chem Neuroanat.*
1068 2013. doi:10.1016/j.jchemneu.2013.03.001

1069 35. Geisler S, Zahm DS. Afferents of the ventral tegmental area in the rat-anatomical
1070 substratum for integrative functions. *J Comp Neurol.* 2005. doi:10.1002/cne.20668

1071 36. Mitchell IJ, Clarke CE, Boyce S, et al. Neural mechanisms underlying
1072 parkinsonian symptoms based upon regional uptake of 2-deoxyglucose in
1073 monkeys exposed to 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. *Neuroscience.*
1074 1989. doi:10.1016/0306-4522(89)90120-6

- 1075 37. Kang Y, Kitai ST. Electrophysiological properties of pedunculopontine neurons
1076 and their postsynaptic responses following stimulation of substantia nigra
1077 reticulata. *Brain Res.* 1990. doi:10.1016/0006-8993(90)91826-3
- 1078 38. Leonard CS, Llinás R. Serotonergic and cholinergic inhibition of mesopontine
1079 cholinergic neurons controlling rem sleep: An in vitro electrophysiological study.
1080 *Neuroscience.* 1994. doi:10.1016/0306-4522(94)90599-1
- 1081 39. Nigro MJ, Mateos-Aparicio P, Storm JF. Expression and functional roles of
1082 Kv7/KCNQ/M-channels in rat medial entorhinal cortex layer II stellate cells. *J*
1083 *Neurosci.* 2014. doi:10.1523/JNEUROSCI.4153-13.2014
- 1084 40. Takakusaki K, Shiroyama T, Kitai ST. Two types of cholinergic neurons in the rat
1085 tegmental pedunculopontine nucleus: Electrophysiological and morphological
1086 characterization. *Neuroscience.* 1997. doi:10.1016/S0306-4522(97)00019-5
- 1087 41. Bordas C, Kovacs A, Pal B. The M-current contributes to high threshold
1088 membrane potential oscillations in a cell type-specific way in the
1089 pedunculopontine nucleus of mice. *Front Cell Neurosci.* 2015.
1090 doi:10.3389/fncel.2015.00121
- 1091 42. Lee AM, Hoy JL, Bonci A, Wilbrecht L, Stryker MP, Niell CM. Identification of a
1092 brainstem circuit regulating visual cortical state in parallel with locomotion.
1093 *Neuron.* 2014. doi:10.1016/j.neuron.2014.06.031
- 1094 43. Chao OY, Pum ME, Li JS, Huston JP. The grid-walking test: Assessment of
1095 sensorimotor deficits after moderate or severe dopamine depletion by 6-
1096 hydroxydopamine lesions in the dorsal striatum and medial forebrain bundle.

- 1097 *Neuroscience*. 2012. doi:10.1016/j.neuroscience.2011.11.016
- 1098 44. Augustine V, Gokce SK, Lee S, et al. Hierarchical neural architecture underlying
1099 thirst regulation. *Nature*. 2018. doi:10.1038/nature25488
- 1100 45. Zhao ZD, Yang WZ, Gao C, et al. A hypothalamic circuit that controls body
1101 temperature. *Proc Natl Acad Sci U S A*. 2017. doi:10.1073/pnas.1616255114
- 1102 46. Amo R, Fredes F, Kinoshita M, et al. The habenulo-raphé serotonergic circuit
1103 encodes an aversive expectation value essential for adaptive active avoidance of
1104 danger. *Neuron*. 2014. doi:10.1016/j.neuron.2014.10.035
- 1105 47. Hikosaka O. The habenula: From stress evasion to value-based decision-making.
1106 *Nat Rev Neurosci*. 2010. doi:10.1038/nrn2866
- 1107 48. Gatto G, Goulding M. Locomotion Control: Brainstem Circuits Satisfy the Need for
1108 Speed. *Curr Biol*. 2018. doi:10.1016/j.cub.2018.01.068
- 1109 49. Maclaren DAA, Santini JA, Russell AL, Markovic T, Clark SD. Deficits in motor
1110 performance after pedunculo-pontine lesions in rats - impairment depends on
1111 demands of task. *Eur J Neurosci*. 2014. doi:10.1111/ejn.12666
- 1112 50. Boucetta S, Cissé Y, Mainville L, Morales M, Jones BE. Discharge profiles across
1113 the sleep-waking cycle of identified cholinergic, GABAergic, and glutamatergic
1114 neurons in the pontomesencephalic tegmentum of the rat. *J Neurosci*. 2014.
1115 doi:10.1523/JNEUROSCI.2617-13.2014
- 1116 51. Kroeger D, Ferrari LL, Petit G, et al. Cholinergic, glutamatergic, and GABAergic
1117 neurons of the pedunculo-pontine tegmental nucleus have distinct effects on

- 1118 sleep/wake behavior in mice. *J Neurosci*. 2017. doi:10.1523/JNEUROSCI.1405-
1119 16.2016
- 1120 52. Mena-Segovia J, Bolam JP. Rethinking the Pedunculopontine Nucleus: From
1121 Cellular Organization to Function. *Neuron*. 2017.
1122 doi:10.1016/j.neuron.2017.02.027
- 1123 53. Galtieri DJ, Estep CM, Wokosin DL, Traynelis S, Surmeier DJ. Pedunculopontine
1124 glutamatergic neurons control spike patterning in substantia nigra dopaminergic
1125 neurons. *Elife*. 2017. doi:10.7554/eLife.30352
- 1126 54. Minamimoto T, Hori Y, Yamanaka K, Kimura M. Neural signal for counteracting
1127 pre-action bias in the centromedian thalamic nucleus. *Front Syst Neurosci*. 2014.
1128 doi:10.3389/fnsys.2014.00003
- 1129 55. Minamimoto T, Hori Y, Kimura M. Roles of the thalamic CM-PF complex-Basal
1130 ganglia circuit in externally driven rebias of action. *Brain Res Bull*. 2009.
1131 doi:10.1016/j.brainresbull.2008.08.013
- 1132 56. Matsumoto N, Minamimoto T, Graybiel AM, Kimura M. Neurons in the thalamic
1133 CM-Pf complex supply striatal neurons with information about behaviorally
1134 significant sensory events. *J Neurophysiol*. 2001. doi:10.1152/jn.2001.85.2.960
- 1135 57. Bradfield LA, Bertran-Gonzalez J, Chieng B, Balleine BW. The Thalamostriatal
1136 Pathway and Cholinergic Control of Goal-Directed Action: Interlacing New with
1137 Existing Learning in the Striatum. *Neuron*. 2013.
1138 doi:10.1016/j.neuron.2013.04.039

- 1139 58. Assous M, Kaminer J, Shah F, Garg A, Koós T, Tepper JM. Differential
1140 processing of thalamic information via distinct striatal interneuron circuits. *Nat*
1141 *Commun.* 2017. doi:10.1038/ncomms15860
- 1142 59. Xiao C, Cho JR, Zhou C, et al. Cholinergic Mesopontine Signals Govern
1143 Locomotion and Reward through Dissociable Midbrain Pathways. *Neuron.* 2016.
1144 doi:10.1016/j.neuron.2016.03.028
- 1145 60. Paxinos G, Franklin KB. Mouse Brain Atlas. *J Neurosci.* 2015.
1146 doi:10.1038/npp.2014.336
- 1147